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GENERAL INTRODUCTION 
 
Neuroendocrine tumors of the pancreas (pNET) are heterogeneous tumors 
originating from the endocrine tissue of the pancreas and accounting for 3-
7% of all pancreatic tumors1, 2. These neoplasms have been regarded as rare 
and present many clinical challenges in diagnosis, classification and 
treatment. They share some common clinical features, frequently have 
unpredictable and unusual biological behavior, and the majority of patients 
present late and have a delayed diagnosis. The incidence of pNET is 
estimated at 2/100.000, with a predicted rise faster than other malignant 
neoplasms3, 4. According to the Surveillance, Epidemiology and End Results 
(SEER) data, the incidence of neuroendocrine tumors (NET) in general has 
shown a 2.7-fold increase between 1973 and 20044. The reason for this 
increase is often explained by improved awareness and the widespread use 
of advanced endoscopic and high-definition radiological imaging3, 5. 
However, several studies also suggest no improvement in outcome of 
patients diagnosed with pNET over a similar period6, 7. PNET in general are 
considered to be indolent, jet some subtypes can be highly malignant and 
resistant to therapy8. Clinical behavior is strikingly divers, with an overall 5-
year survival varying from 97% for insulinomas to 30% for non-functioning 
tumors who are clinically silent9. These data necessitate reconsideration of 
the idea that pNET are slow growing, fairly benign lesions.  
 
Nomenclature 
The nomenclature of neuroendocrine neoplasms (NENs) has evolved 
considerably over the last two decades. Siegfried Oberndorfer is the first who 
described and depicted NENs in 1907. He initially considered them benign 
and “carcinoma-like”, calling them carcinoids, before detailing their 
malignant behavior in 1929. NEN of the pancreas were often called “islet cell 
tumor”, which denotes the presumed origination in the islets of Langerhans. 
The use of both terms has generally declined; however "carcinoid syndrome" 
is still used frequently  as a generic description for a characteristic syndrome 
that results from hormonal overproduction that occurs in some patient with 
NEN10. In recent years, the term "pancreatic neuroendocrine tumor” has been 
adopted by most practitioners, as well as by the European Neuroendocrine 
Tumor Society (ENETS) and the World Health Organization (WHO), for well-
differentiated tumors regardless of histologic grade. The term “pancreatic 
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neuroendocrine carcinoma” (NEC) is reserved for those cases with poorly 
differentiated histology and a high proliferative rate.  
 
Clinical presentation and diagnosis 
Based on the hormonal overproduction and associated clinical syndrome, 
pNET can be divided in functional (F-pNET) and non-functional (NF-pNET) 
tumors11, 12. Patients with functional tumors show symptoms due to 
hypersecretion of peptides and amines such as hypoglycemia as a result of 
increased insulin levels caused by an insulinoma or the Zollinger-Ellison 
syndrome caused by excessive gastrin production by a gastrinoma. Other, 
less common, functional pNET include VIPoma, glucagonom and ACTHoma. 
The majority of pNET (70-80%) are non-functional and do not secrete 
hormones that cause symptoms4, 13, 14. As a result, many are clinically silent 
until late presentation. These patients are either incidentally diagnosed 
through radiological imaging performed for unrelated conditions or present 
with symptoms of mass effects or distant (usually hepatic) metastases, or 
both6, 15. Symptoms usually consist of abdominal pain, weight loss, anorexia 
and nausea11. Several analyses have shown that approximately 65% of 
patients with non-functioning tumors are diagnosed with distant metastases, 
resulting in unfavorable prognosis4, 7, 14, 16. A small subgroup of patients with 
pNET is known with hereditary tumor syndromes such as Multiple Endocrine 
Neoplasia Type 1 (MEN-1) or Von Hippel Lindau disease (VHL). These 
patients may develop multiple well-differentiated functional or non-functional 
tumors in the pancreas. 
 
Diagnosis of pNET is based on clinical presentation, hormone assays and 
pathology. A variety of biomarkers may be used to aid the diagnosis and 
post-treatment follow-up. Chromogranin A (CgA) is the most commonly 
secreted and measured tumor marker associated with NEN in the 
gastroentero-pancreatic tract. This glycoprotein is normally contained in 
neuroendocrine cell vesicles and is often elevated in patients with pNET. 
Plasma levels of CgA are thought to correlate with tumor burden, and some 
studies show a higher overall diagnostic sensitivity in patients with metastatic 
disease compared to patients with localized disease, although other studies 
show conflicting results17-20. Overall, the general accuracy of CgA is moderate 
as false positive increased levels of CgA often occur15, 21, 22. 
 
To diagnose pNET, appropriate cross-sectional imaging is recommended for 
all patients. Technical developments in radiological imaging have facilitated 
the characterization and detection of primary pancreatic NETs and liver 
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metastases over the last few decades. Computed tomography (CT) with 
intravenous contrast, magnetic resonance imaging (MRI) and endoscopic 
ultrasound (EUS) show the highest sensitivity and specificity, making it 
appropriate initial diagnosis, surgical planning and follow-up of primary 
tumors, distant metastases or after surgical resection23-25. Since somatostatin 
receptors are highly expressed on most neuroendocrine tumors, 
somatostatin-receptor scintigraphy (Octreoscan®) can be used for optimal 
staging and determining eligibility for nuclear treatment that targets these 
receptors. Position emission technology (PET) used to be recommended only 
for the diagnosis or staging of poorly differentiated NEC. However, the use of 
68Gallium as a positron emitter showed higher spatial resolution and image 
quality compared to Octreoscan, making it the recommended imaging 
modality to aid detection and staging of pNET26, 27. 
 
Pathology and prognosis 
One of the concerns with pNET is the accurate prediction of clinical outcome. 
Tumor stage and grade have proven to be useful in estimating disease course 
and have been confirmed repeatedly in valuable studies11, 28-32. Staging is 
performed using the tumor, node, metastasis (TNM) classification, recently 
updated to incorporate ENETS definitions33. Tumor grade is an estimate of 
malignant potential and divides pancreatic NEN into prognostic groups 
based on the expression of the nuclear antigen Ki67. Well differentiated pNET 
are separated into G1 (low-grade) with a Ki67 expression <3% and G2 
(intermediate-grade) with a Ki67 expression of 3-20%. High-grade pancreatic 
neoplasms expressing Ki67 >20% are classified as G3, of which the WHO 
recently has updated their classification dividing these tumors into G3 NET 
and G3 NEC34. G3 NET are well-differentiated and have a Ki67 in the 20-55% 
range, whereas poorly differentiated G3 NEC have higher Ki67 values and 
poorer prognosis. 
 
Treatment 
Lack of data on pNET disease poses challenges for treatment and clinical 
decision making, often based on experience and expert opinion rather than 
high-level scientific evidence. Treatment should be individualized and 
managed in a multidisciplinary setting based on the tumor burden and 
symptoms. The best therapeutic choice will depend on whether the main aim 
is to cure, to slow tumor growth and improve oncological outcome or improve 
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the quality of life by inhibition of hormonal overproduction or refrain from 
surgical resection with possible adverse events.  
 
Surgery is essential in many stages of pNET management and remains the 
only curative treatment option9. Based on tumor location and size, different 
surgical procedures are available: pancreatoduodenectomy, total, central or 
distal pancreatectomy and enucleation, either performed open or 
laparoscopically. All except for the latter technique usually includes 
lymphadenectomy of locoregional lymph nodes, although clear consensus 
on location and total number to harvest is not available. Pancreatic surgery 
is often associated with complications, mainly consisting of pancreatic 
fistula, delayed postoperative emptying and postoperative bleeding. Because 
patients with pNET who undergo surgery have a relatively good survival, long 
term complications consisting of endocrine or exocrine pancreatic 
insufficiency can be developed.   
 
The management of incidentally discovered small NF-pNET is under debate. 
A growing body of literature show little to no tumor progression in pNET <2cm 
of size and suggests safety in surveillance 35, 36. In contrast, other studies 
advocate that surgical resection is the best curative option for all pNET, 
including the small tumors36-38. Although the risk of malignant potential still 
remains unknown for NF-pNET <2cm with respect to tumors >2cm, and the 
benefits due to adopting a more conservative strategy have not been 
described, the ENETS has updated their guidelines advocating the possibility 
of surveillance in small pNET. Prospective studies are necessary to provide 
insight on the optimal management of NF-pNET <2cm. 
 
Follow-up and recurrence 
Until recently, recurrence was generally considered to be uncommon, making 
is unnecessary for patients to be monitored after resection. Currently, it is 
assumed that early detection and treatment of pNET recurrence will lead to 
a favorable outcome, although supportive data is missing. Follow-up is 
therefore designed to monitor patients and optimize oncologic outcome39-41. 
Nevertheless, clear consensus on follow-up has not yet been reached and 
multiple international guidelines provide different recommendations on the 
frequency, modality and duration of follow-up for different stages of disease. 
Commonly, follow-up is the same for all patients who have undergone a 
curative resection of pNET. Although tumor stage and grade have proven to 
be useful in estimating disease course, postoperative surveillance protocols 
or adjuvant treatment options based on the expected recurrence rates are 
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not available. Reliable recurrence rates are difficult to deduct from literature 
because of the rarity of the disease and the inhomogeneous group of patients 
with resected pNET. The majority of published studies include patients with 
hereditary syndromes, distant metastases or locally advanced disease, who 
have been known to have a different probability of tumor recurrence and 
survival. 
 
 
AIM AND OUTLINE OF THIS THESIS 
 
This thesis aims to provide insight into the postoperative outcome of patients 
who have undergone a curative resection of well-differentiated pNET. 
Curative resection is defined as a complete resection (R0 or R1 resection42) 
of localized G1/G2 pNET, as surgery is considered the only curative treatment 
option available. High-grade pNET, patients with distant metastases 
(regardless of complete metastasecomy) and hereditary syndromes are not 
included as these tumors are known for their highly malignant behavior, 
frequent recurrences and unfavorable prognosis, making it difficult to 
curatively treat these patients. Some studies in this thesis include only NF-
pNET to limit the heterogeneity of the patient population. Because NF-pNET 
do not have an overproduction of hormones and the accompanying clinical 
symptoms, the presentation of recurrences is often delayed compared to 
patients with F-pNET. For this reason, it is believed that the survival of 
patients with NF-pNET is worse, despite the assumption of similar 
pathophysiology, emphasizing the need for (improved) detection possibilities 
for recurrence.  
 
In Chapter 2 an overview of the treatment and related survival of pNET in the 
Netherlands from 2008-2013 is provided. Chapter 3 presents the results of 
a systematic review and meta-analysis on recurrence after curative resection 
of well-differentiated pNET. In Chapter 4 the Recurrence Score is introduced, 
an easy tool to estimate the risk of recurrence after curative resection of 
G1/G2 NF-pNET and identify high-risk patients. A method to alter this scoring 
system is described in Chapter 5, in which the Ki67 proliferation index is 
analyzed with regards to recurrence after complete resection of pNET with 
Ki67 of 0-20%. Chapter 6 investigates the utility of a multianalyte blood-test, 
the NETest, during postoperative follow-up of pNET. The results of a 
consensus study with a large group of international NET experts are 
presented in Chapter 7. Eleven recommendations were formulated that may 
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13 
lower the threshold for future researchers to investigate the role of adjuvant 
treatment for patients with a high-risk of recurrence. Chapter 8 presents the 
PANDORA study, a prospective nationwide observational cohort of patients 
with small pNET to investigate the effect of a conservative vs. surgical 
treatment for non-functioning tumors<2cm. 
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ABSTRACT 
 
Background. Large population based studies give insight in the prognosis 
and treatment outcomes of patients with pancreatic neuroendocrine tumors 
(pNET). Therefore, we provide an overview of the treatment and related 
survival of pNET in the Netherlands. 
 
Methods. Patients diagnosed with pNET between 2008-2013 from the 
Netherlands Cancer Registry were included. Patient, tumors and treatment 
characteristics were reported. Survival analyses with Log-rank testing were 
performed to compare survival. 
 
Results. In total, 611 patients were included. Median follow-up was 25.7 
months, and all-cause mortality was 42%. Higher tumor grade and TNM-
stage were significantly associated with worse survival in both the overall and 
metastasized population. The effect of distant metastases on survival was 
more significant in lower tumor stages (T1-3 p<0.05, T4 p=0.074). Resection 
of the primary tumor was performed in 255 (42%) patients. Patients who 
underwent surgery had the highest 5-year survival (86%) compared to PRRT 
(33%), chemotherapy (21%), targeted therapy (NR) and somatostatin 
analogs (24%) (all p<0.001). Patients with T1M0 tumors (n=115) showed 
favorable survival after surgical resection (N=95) compared to no therapy 
(N=20, p=0.008). Resection also improved survival significantly in patients 
with metastases compared to other treatments (all p>0.05). Without surgery, 
PRRT showed the best survival curves in patients with distant metastases. 
Grade 3 tumors and surgical resection were independently associated with 
survival (HR 7.23 and 0.12, respectively).  
 
Conclusion. Surgical resection shows favorable outcome for all pNET 
tumors, including indolent tumors and tumors with distant metastases. 
Prospective trials should be initiated to confirm these results. 
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INTRODUCTION 
 
According to Surveillance, Epidemiology and End Results (SEER) data, the 
incidence of neuroendocrine tumors (NET) showed a 2.7-fold increase 
between 1973-2004 [1]. The incidence of pancreatic NET (pNET) is estimated 
at 2/100.000, with a predicted rise faster than other malignant neoplasms [2]. 
Although pNET in general are considered to be indolent, some subtypes can 
be highly malignant and resistant to therapy [3]. As the majority of tumors are 
not associated with secretion of hormones that cause clinical symptoms, 
patients are predominantly diagnosed with disseminated disease for whom 
curation is not possible [4, 5]. SEER analyses demonstrate that 64% of 
patients with well-differentiated (G1 and G2) pNET are diagnosed with distant 
metastases and have a poor 5-year survival of 27%. For these patients, 
different treatment options are available in order to reduce tumor load, to 
inhibit tumor growth or to alleviate symptoms. Treatment options include 
somatostatin receptor analogs (SSA), targeted therapy, chemotherapy or 
peptide receptor radionuclide therapy (PRRT).  
 
Our knowledge on pNET has improved considerably in the last decade, as is 
evident from the fast development of staging and grading systems proposed 
by the World Health Organization (WHO), the European Neuroendocrine 
Tumor Society (ENETS) and the American Joint Committee on Cancers 
(AJCC). In the present study, we provide an overview of patients diagnosed 
with pNET in the Netherlands identified through the nationwide Netherlands 
Cancer Registry (NCR). The NCR covers the complete Dutch population and 
receives lists of newly diagnosed cancer cases from the nationwide 
Automated Pathology System (PALGA) on a weekly basis [6]. In addition, lists 
of discharged cancer patients from the national registry of hospital discharge 
diagnosis are obtained to capture pNET cases with only a clinical diagnosis 
[7]. Checks on completeness of the data shows a national coverage of about 
95% [8][9]. We aim to provide more insight in the treatment related survival 
of patients with pNET. This knowledge will support decisions on treatment 
regimens and help identify priorities in research for the future. To our 
knowledge, this is the first comprehensive survey on pNET epidemiology in 
the Netherlands. 
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METHODS 
 
Cases of pNET diagnosed from January 2008 to December 2013 were 
obtained from the nationwide, population based NCR database, managed by 
the Netherlands Comprehensive Cancer Organization (IKNL). Registration 
and coding in this registry was conducted according to the guideline of the 
WHO and the International Association of Cancer Registries [10]. Topography 
and histology were coded according to the International Classification of 
Diseases for Oncology, third edition (ICD-O-3) [11]. To identify patients with 
neuroendocrine tumors of the pancreas (ICD-O-3 codes C251, C252, C254, 
C258 and C259) were combined with histology codes (8000-8011, 8013, 
8041-8044, 8150-8153, 8155-8157, 8240-8242, 8246-8249, 8574 and 9990) 
from the PALGA network. Clinical and pathological information was obtained 
from hospital records.  
 
Only patients with pancreatic NET were included. NET of other origin, as well 
as patients diagnosed from postmortem autopsies and tumors with mixed 
histology, such as adenocarcinoma of the pancreas, were excluded. Tumor-
Node-Metastasis (TNM) assessment was based on the TNM-classification 
6th edition proposed by ENETS [12]. Missing TNM-stage was assessed using 
supplementary data on “extend of disease” present in the NCR database. In 
addition, unrecorded data on TNM-classification, tumor size and resection 
margins for surgically resected tumors were requested from all pathology 
centers and manually complemented for each patient. Data on functionality 
of the tumors was not present in the registry. Tumors were considered 
localized when the malignant tissue was confined to the pancreas, regional 
if there was extension into adjacent organs or metastasis to regional lymph 
nodes, and distant if metastasis to other organs was present. Grading was 
performed using the WHO grading system from the time of diagnosis, 
meaning that patients diagnosed before 2010 were graded according to the 
WHO 2004 grading system, and patients diagnosed in 2010 and later using 
the WHO 2010 grading system. First-line treatment of all patients was 
recorded. Surgery was defined as surgical resection of the primary tumor. 
Patients who underwent resection of distant metastases were excluded from 
this category, as well as patients who underwent bypass surgery or an 
endoscopic procedure without resection of the tumor. Targeted therapy 
included either treatment with a tyrosine/kinase inhibitor (-nib) or everolimus. 
Other treatments included peptide receptor radionuclide therapy (PRRT), 
chemotherapy or somatostatin analogs (SSA). 
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Statistical analyses were performed using SPSS Statistics for Windows 
version 23.0 (IBM Corp. Armonk, NY). On the basis of the distribution, data 
was described as median with interquartile range (IQR) for skewed 
distributions and as mean with standard deviation (SD) for normal 
distribution. For categorical data, the number and proportion (%) was 
displayed. Differences between patient-groups based on tumor 
characteristics were investigated using a chi-square statistic.  Kaplan-Meier 
curves were plotted and Log-rank statistics computed to detect differences 
between survival curves for various sub-populations. Survival was defined as 
the time from diagnosis until death (if known) or last follow-up (last known 
alive date, or 31 December 2013). Median survival was defined as the length 
of time, from the date of diagnosis, that half of the patients are still alive. 
Univariable and multivariate Cox proportional hazards regression models 
were used to estimate hazard ratios (HR) with 95% confidence intervals 
(95%CI) for factors associated with survival.  
 
 
RESULTS 
 
Demographics 
Patient, tumor and treatment characteristics are presented in Table 1. In total, 
611 patients diagnosed with pNET were included in the analyses. The 
diagnosis pNET was made at an academic hospital in 36% and in a 
peripheral hospital in 63% of cases. Treatment was received more often in 
an academic hospital (46% vs. 30% peripheral hospital). Median follow-up 
was 25.7 months (IQR 10-45 months), all-cause mortality was 42%. Patients 
were diagnosed with distant metastases in 53% in 2008 and 44% in 2013 
(p=0.390). Most patient had a grade 1 tumor (32%). Nodal metastases were 
seen in 23% of G1 tumors, 43% of G2 tumors and 71% of G3 tumors, 
respectively (p<0.001). Distant metastases were present in 25% of G1, 51% 
of G2 and 71% in G3 tumors (p<0.001). Nodal or distant metastases were 
significantly more frequent in patients with higher tumor stage (both 
p<0.001). Patients with positive lymph nodes also had distant metastases in 
62%, whereas node negative patients had distant metastases in 27% 
(p<0.001).  
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 Table 1 – Patient, tum
or and treatm
ent characteristics 
 
Data available 
N (%
) 
Overall 
Surgery 
PRRT 
Chem
otherapy 
Targeted 
therapy 
SSA 
No therapy 
 N  
  
 611 
 255 (42%
) 
 41 (7%
) 
 44 (7%
) 
 21 (3%
) 
 62 (10%
) 
 150 (25%
) 
Year of diagnosis 

2008 

2009 

2010 

2011 

2012 

2013 
611 (100%
) 
 64 (11%
) 
90 (15%
) 
97 (16%
) 
105 (17%
) 
135 (22%
) 
120 (20%
) 
 17/64 (27%
) 
44/90 (49%
) 
32/97 (33%
) 
51/105 (49%
) 
59/135 (44%
) 
52/120 (43%
) 
 
10/64 (16%
) 
7/90 (8%
) 
9/97 (9%
) 
5/105 (5%
) 
4/134 (3%
) 
6/120 (5%
) 
 7/64 (11%
) 
8/90 (9%
) 
8/97 (8%
) 
7/105 (7%
) 
8/120 (6%
) 
6/120 (5%
) 
 
0 (0%
) 
2/90 (2%
) 
2/97 (2%
) 
3/105 (3%
) 
8/135 (6%
) 
6/120 (5%
) 
 
7/64 (11%
) 
7/90 (7%
) 
8/97 (8%
) 
12/105 (11%
) 
14/135 (10%
) 
14/120 (12%
) 
 
16 (25%
) 
16/90 (18%
) 
36/97 (37%
) 
12/105 (11%
) 
35/135 (26%
) 
24/120 (21%
) 
M
edian age (range) 
611 (100%
) 
62 (53-71) 
59 (19-81) 
57 (38-85) 
60 (38-81) 
60 (63-82) 
67.5 (40-87) 
69 (20-90) 
Gender 

M
ale 

Fem
ale 
611 (100%
) 
 314 (51%
) 
297 (49%
) 
 
121 (48%
) 
134 (53%
) 
 
20 (49%
) 
21 (51%
) 
 26 (59%
) 
18 (41%
) 
 
8 (38%
) 
13 (62%
) 
 
40 (65%
) 
22 (36%
) 
 
74 (49%
) 
76 (51%
) 
Tum
or grade 

G1 

G2 

G3 
348 (57%
) 
 
197 (32%
) 
101 (17%
) 
50 (8%
) 
 
143 (56%
) 
56 (22%
) 
12 (5%
) 
 
6 (15%
) 
7 (17%
) 
1 (2%
) 
 
3 (7%
) 
2 (5%
) 
11 (25%
) 
 
2 (10%
) 
8 (38%
) 
3 (14%
) 
 
18 (29%
) 
16 (26%
) 
0 (0%
) 
 
20 (13%
) 
8 (5%
) 
19 (13%
) 
T-stadium
 

T1 

T2 

T3 

T4 
462 (76%
) 
 131 (22%
) 
172 (28%
) 
117 (19%
) 
42 (7%
) 
 
99 (39%
) 
82 (32%
) 
62 (24%
) 
3 (1%
) 
 
0 (0%
) 
12 (29%
) 
6 (15%
) 
4 (10%
) 
 
1 (2%
) 
10 (23%
) 
8 (18%
) 
6 (14%
) 
 
1 (5%
) 
6 (29%
) 
8 (38%
) 
2 (10%
) 
 
1 (2%
) 
17 (27%
) 
10 (16%
) 
13 (21%
) 
 
28 (19%
) 
38 (25%
) 
16 (11%
) 
10 (7%
) 
N-stadium
 

N0 

N+ 
479 (81%
) 
 
315 (52%
) 
182 (30%
) 
 
181 (71%
) 
69 (27%
) 
 
14 (34%
) 
10 (24%
) 
 
16 (36%
) 
15 (34%
) 
 
11 (52%
) 
6 (29%
) 
 
22 (36%
) 
18 (29%
) 
 
62 (41%
) 
47 (43%
) 
M
-stadium
 

M
0 

M
+ 
246 (96%
) 
 
314 (51%
) 
290 (48%
) 
 
232 (91%
) 
20 (8%
) 
 
9 (22%
) 
31 (76%
) 
 
3 (7%
) 
40 (91%
) 
 
1 (5%
) 
20 (95%
) 
 
7 (11%
) 
55 (89%
) 
 
50 (33%
) 
98 (65%
) 
Deaths 
611 (100%
) 
259 (42%
) 
35 (14%
) 
20 (49%
) 
39 (89%
) 
12 (57%
) 
33 (53%
) 
98 (65%
) 
5-year survival 
 
53%
 
86%
 
33%
 
21%
 
Not reached 
24%
 
30%
 
M
edian survival 
 
25.7 m
onths 
36.2 m
onths 
43.6 m
onths 
7.6 m
onths 
16.2 m
onths 
23.1 m
onths 
9.9 m
onths 
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Figure 1 - Overall survival of patients with different tumor grades. A Overall patient population. 
B Patient with metastatic disease.  
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Survival 
Overall, 5-year survival was 53%. There was no significant difference in 
overall survival for patients diagnosed in different years separately analyzed. 
Five-year survival was 78% without and 27% with distant metastases 
(p<0.001). In the absence of lymph node metastases 5-year survival was 
72%, compared to 44% in patients with nodal metastases (p<0.001). In the 
absence of distant metastases, positive lymph nodes had a significant 
negative effect on survival (p=0.003). With distant metastases, the effect of 
lymph node metastases on survival was not significant, however close 
(p=0.053).  
 
A higher tumor grade was associated with worse survival, in both localized 
as well as distant metastatic disease (Fig 1). Overall, 5-year survival was 80% 
for G1, 67% for G2 and 13% for G3 tumors. Median survival was decreased 
by 7.4 months for G1 (p<0.001), 11.3 months for grade 2 (p<0.001) and 12.4 
months for grade 3 tumors (p=0.022) in the presence of distant metastases. 
Nodal metastases (N0 vs N1) were not associated with a survival difference 
of patient with different tumor grade.  
 
Survival was worse with higher tumor stage in patients with localized disease 
(Fig. 2A). Five-year survival was 79% for T1, 67% for T2, 52% for T3 tumors 
and 30% for T4 tumors. In the presence of distant metastases, increase of 
tumor stage showed no worsening of survival (Fig 2B.). Median survival with 
and without distant metastases was 33.1 vs. 10.1 months for T1 tumors 
(p<0.001), 36.3 vs. 9.2 months for T2 tumors (p<0.001) and 25 vs. 16.6 
months for T3 tumors (p=0.002), respectively. In T4 tumors, M0 and M1 
patients had comparable survival curves (P=0.074). 
 
Surgical and other treatment 
Resection of the primary tumor was performed in 255 cases (25%). The 
number of patient who underwent surgery increased from 27% in 2008 to 
43% in 2013 (p=0.02). Chemotherapy, PRRT, targeted therapy or SSA was 
received by 168 patients. Hundred-fifty patients received no treatment. 
Patient and tumor characteristics per treatments are presented in table 1. 
Tumor size was only known for patients who underwent surgical resection. 
Lymph node metastases were detected in 16% of tumors <2cm, 38% of 
tumors of 2-4cm and 37% of tumors >4cm of size (p=0.002). 
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Figure 2 - Overall survival of patients with different tumor stages. A Overall patient population. 
B Patients with metastatic disease. No significant difference in survival was seen between each 
tumor stage. 
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Overall, survival was favorable for patients who underwent surgical resection 
of the primary tumor compared to PRRT, chemotherapy, targeted therapy, 
SSA and no therapy (all p<0.001. Fig 3A). For patients with the most indolent 
tumors (T1M0) a significant survival benefit was seen for surgical resection 
compared to no treatment (p=0.008), with a 5-year survival of 91% vs. 65% 
(Fig 4 – T1M0). Focusing on patients with distant metastatic disease, surgical 
resection of the primary tumor showed a significant better survival, with a 5-
year survival of 90% compared to 50% for PRRT (p=0.016), 29% for SSA 
(p<0.001) and 14% for no therapy (p<0.001) (Fig 3B). Five-year survival of 
patients receiving chemotherapy (p<0.001) or targeted therapy (p=0.002) 
was not reached. When surgical resection was not performed in the presence 
of distant metastases, patients who received PRRT showed significant better 
survival compared to chemotherapy (p<0.001) or SSA (p=0.04) but not to 
targeted therapy (p=0.062). Tumor grade significantly differed in this 
population between patients who received PRRT and chemotherapy 
(p=0.002) and between chemotherapy and targeted therapy (p=0.017). Other 
patient and tumor characteristics were not significantly different between the 
treatment groups.  
 
Predictors for survival 
Age at diagnosis, tumor grade, tumor stage, lymph node metastases, distant 
metastasis and first line treatment showed an association with survival in 
univariable analysis. Multivariable analysis showed that G3 tumors (HR 7.23, 
95%CI 3.25-16.13) and surgical resection (HR 0.12, 95%CI 0.05-0.30) were 
independently associated with survival (Table 3). Excluding G3 tumors from 
multivariable analysis resulted in comparable results for surgical resection 
(HR 0.12, 95%CI 0.04 – 0.38) and only an additional significance for age 
without clinical relevance (HR 1.03, 95%CI 1.00 – 1.07). 
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Figure 3 - Overall survival of patients based on first line treatment. A All patients; Surgical 
resection showed significantly superior survival compared to the other treatments (all p<0.001). 
B Patients with distant metastases. 
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Table 2 - Cox Regression Analysis 
Risk factors Univariable   Multivariable  
 HRs 95%CI p-value  HRs 95%CI p-value 
 
Gender 
 
1.03 
 
0.81 – 1.31 
 
0.817  
 
- 
 
- 
 
- 
Age at diagnosis 1.04 1.03 – 4.05 <0.001  1.03 1.00 – 1.05 0.076 
Year of diagnosis 
 2008 
 2009 
 2010 
 2011 
 2012 
 2013 
 
ref. 
0.92 
0.95 
0.67 
0.93 
0.93 
 
ref. 
0.60 – 1.43 
0.61 – 1.48 
0.42 – 1.07 
0.60 – 1.44 
0.58 – 1.50 
 
ref. 
0.73 
0.81 
0.09 
0.74 
0.77 
  
- 
 
- 
 
- 
Tumor grade 
 G1 
 G2 
 G3 
 
ref. 
1.87 
11.1 
 
ref. 
1.13 – 3.10 
7.0 – 17.57 
 
ref. 
0.015 
<0.001 
  
ref. 
1.36 
7.23 
 
ref. 
0.63 – 2.94 
3.25 – 16.13 
 
ref. 
0.431 
<0.001 
Tumor stage 
 T1 
 T2 
 T3 
 T4 
 
ref. 
1.75 
2.39 
4.25 
 
ref. 
1.11 – 2.77 
1.50 – 3.82 
2.49 – 7.26 
 
ref. 
0.016 
<0.001 
<0.001 
  
ref. 
0.73 
1.10 
0.90 
 
ref. 
0.31 – 1.72 
0.46 – 2.63 
0.28 – 2.89 
 
ref. 
0.465 
0.826 
0.863 
Nodal status 2.62 1.95 – 3.54 <0.001  1.22 0.68 – 2.16 0.507 
Distant metastasis 4.79 3.60 – 6.37 <0.001  1.25 0.56 – 2.77 0.587 
First line treatment 
 No therapy 
 Surgical resection 
 PRRT 
 Chemotherapy 
 Targeted therapy 
 SSA 
 
ref. 
0.12 
0.42 
1.63 
0.75 
0.58 
 
ref. 
0.08 – 0.18 
0.26 – 0.68 
1.12 –2.38 
0.41 – 1.37 
0.39 – 0.87 
 
ref. 
<0.001 
<0.001 
0.011 
0.347 
0.008 
  
ref. 
0.12 
0.76 
0.49 
0.75 
0.84 
 
ref. 
0.05 – 0.30 
0.23 – 2.50 
0.20 – 1.19 
0.21 – 2.67 
0.29 – 2.42 
 
ref. 
<0.001 
0.649 
0.115 
0.656 
0.743 
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Figure 4 - Survival of patients with T1M0 tumors. 
 
 
DISCUSSION  
 
In this study, we present the treatment and survival of patients diagnosed 
with pNET in the Netherlands over a 6 year period. Patients undergoing 
surgical resection show superior outcomes in terms of survival, regardless of 
the presence of distant metastases. Apart from surgery and allowing for 
selection bias, PRRT shows the best survival curves in patients with 
disseminated disease.  
 
For a long time, surgical treatment was the golden standard for patients 
diagnosed with localized pNET. However, there have recently been changes 
in the guidelines advising a conservative, rather than a surgical approach, for 
small non-functional tumors [13]. Data supporting this observational option 
are controversial as is evident from the presented results: T1M0 patients with 
a resection have a survival benefit compared to those without treatment. Still, 
issues of selection bias, small sample and missing data limit our ability to 
make valid conclusions. Similar studies support or contradict our findings, 
indicating comparable study bias and the need for prospective data [14-16]. 
It is imaginable that the reason to refrain from surgery might influence the 
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outcome in both directions. As there are no RCTs or meta-analyses that can 
assist the optimal management of small pNET, a prospective study to register 
and monitor all patients with small pNET (the PANDORA-study) is currently 
being conducted in the Netherlands. 
 
A more aggressive approach has increasingly been described in the literature 
with regards to metastasized disease [17-20]. Similarly, our results promote 
surgical resection for patients with distant metastases, with a survival benefit 
of 40-76% in 5 years. Inclusion bias, with relative stable M1 patients, 
warrants that future studies clearly describe patients related treatment 
determinants, tumor progression and time to progression as markers. 
Definitions of metachronous and synchronous metastases should be 
established, preferably in international guidelines, for research to be univocal 
and comparable. Only then, the presented results can be confirmed in 
prospective trials that weigh the effect of resection in the presence of 
metastases (i.e. resection of the primary tumor with/without synchronous 
resection of solitary liver metastases) against the current, less invasive, 
systemic and nuclear options, taking into account the risks of both 
treatments. 
 
The effect of PRRT has not previously been described in a population-based 
study. In this cohort, 41 patients received treatment with PRRT and showed 
the longest median survival compared to other treatments. Furthermore, 
survival analyses showed that PRRT had comparable outcomes to surgical 
resection in the overall population, and favorable outcome in patients with 
distant metastatic disease who did not undergo surgery. Nevertheless, there 
is a clear selection bias since less G3 tumors received PRRT compared to 
chemotherapy, implying that the favorable outcome of PRRT might be 
explained by the selection of patients with less aggressive disease. 
Significant differences for tumor grade between the treatment groups 
support this theory. Unfortunately, the available data was too small to provide 
reliable sub-analyses on tumor grade for the non-surgical treatment groups.  
 
The results of this study must be seen in light of its limitations. Data were 
evaluated retrospectively and pathology reports were not standardized at the 
time of treatment. This may explain the considerable amount of missing data 
for tumor stage and grade, as other population based studies also report [1, 
21]. It is worth mentioning that registration improved up to 78% for grade 
and 89% for tumor stage in 2013. An additional increase is anticipated in the 
Netherlands as national pathological guidelines for pNET have been 
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published the in 2013, and 4 hospitals have been named ENETS Centers of 
Excellence after the study period. Nevertheless, the amount of patients 
treated in non-academic centers show that there may be bias due to lack of 
centralization, as pNET requires complex knowledge and care. Furthermore, 
heterogeneity remains a difficult and recurring issue in pNET research.  
Accurate assessment of patient and tumor characteristics, along with strict 
selection criteria in future studies should be pursued to limit bias and draw 
reliable conclusions from study results.  
 
Conclusion and future perspectives  
Despite efforts, the overall survival of patients diagnosed with pNET is not 
improving. An effective and purposeful treatment approach is therefore 
necessary. Besides survival, patient related outcomes should be included in 
future studies. Tumor grade and TNM-stage remain the most important 
prognostic factors, and need to be clearly defined in each patient, to 
determine prognosis and treatment. Surgical treatment of small pNET and 
patients with M1 disease improves survival compared to all other treatments. 
Prospective trials must be encouraged to achieve fast and reliable results. 
Emphasis of future research should be on whether or not to resect pNET in 
patients with small lesions as well as patients with distant metastatic disease. 
Clear definitions for synchronous/metachronous lymph node and distant 
metastases, time to progression and treatment indication should be 
established and used in all studies concerning pNET. 
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ABSTRACT 
 
Objective. To predict recurrence in patients with grade 1 or 2 non-functioning 
pancreatic neuroendocrine tumors (NF-pNET) after curative resection. 
 
Background. Surgical resection is the preferred treatment for NF-pNET, 
however recurrence still occurs frequently after curative surgery, worsening 
prognosis of patients. 
 
Methods.  Retrospectively patients with NF-pNET of three institutions were 
included. Patients with distant metastases, hereditary syndromes or grade 3 
tumors were excluded. Local or distant tumor recurrence was scored. 
Independent predictors for survival and recurrence were identified using Cox-
regression analysis. The recurrence-score was developed to predict 
recurrence within 5-years after curative resection of grade 1-2 NF-pNET. 
 
Results. With a median follow-up of 51 months, 211 patients with grade 1-2 
NF-pNET were included. Thirty-five patients (17%) developed recurrence. 
The 5- and 10-year disease specific/overall survival was 98%/91% and 
84%/68%. Predictors for recurrence were tumor grade 2, lymph node 
metastasis and perineural invasion. Based on these predictors the 
recurrence-score was made. Discrimination (c-statistic 0.81, CI95% 0.75-
0.87) and calibration (Hosmer Lemeshow chi-square 11.25, p=0.258) 
indicated that the ability of the recurrence-score to identify patients at risk for 
recurrence is good. 
 
Conclusion. This new scoring system could predict recurrence after curative 
resection of grade 1 and 2 NF-pNET. With the use of the recurrence-score 
less extensive follow-up could be proposed for patients with low recurrence-
risk. For high-risk patients, clinical trials should be initiated to investigate 
whether adjuvant therapy might be beneficial. External validation is ongoing 
due to limited availability of adequate cohorts. 
 
 
  
04 04 
A new scoring system to predict recurrent disease in grade 1 and 2 NF-pNET 
	 57 
INTRODUCTION 
 
In patients with curative resected non-functional pancreatic neuroendocrine 
tumor (NF-pNET), the overall prognosis is usually favorable. Currently The 
main focus during follow-up is to detect recurrence at an early stage1-3. 
However, follow-up regimens after resection of pNET are generally the same 
and no distinction is made between patients based on the presence or 
absence of specific tumor characteristics. In addition, Reliable recurrence 
rates are difficult to deduct from literature, because of the rarity of the disease 
and the inhomogeneous group of patients with resected pNETs. Most studies 
include patients with hereditary syndromes, hormonal overproduction, 
incidentally detected pNET and patients with metastases or locally advanced 
disease4-8. All these patients have a different probability of tumor recurrence 
and survival.  
 
In the general practice, knowledge about the prognosis of a patient provides 
support when determining the frequency of the follow-up visits. Better 
estimation of long-term results prognosis of curable patients is therefore 
desirable. With this knowledge, postoperative management can be 
customized based on the expected risk of recurrence, as is common in some 
other malignancies9. This approach can have advantages for the patient as 
well as the hospital and the health care system. Despite international 
guidelines10,11, there is still much uncertainty about the frequency of follow-
up visits and radiological imaging. Current European Neuroendocrine Tumor 
Society (ENETS) and North American Neuroendocrine Tumor Society 
(NANETS) guidelines provide recommendations on the management of pNET 
but do not include statements on postoperative follow-up regimens. 
Moreover, the latest guidelines propose a conservative approach in the 
surgical management of small tumors <2cm. This opinion is based on 
retrospective analyses and the indolent nature of these tumors. This strategy 
could be adopted for a select group of patients after surgical resection of 
tumors without unfavorable characteristics. 
 
In comparison with other types of cancer, including pancreatic cancer, 
adjuvant treatment after surgical resection is not recommended for patients 
with NF-pNET4. In metastatic patients, different treatment options are 
available in order to reduce tumor load, to inhibit tumor growth or to alleviate 
the symptoms12. These include chemotherapy13,14, long acting somatostatin 
analogues15,16, mTOR or tyrosine kinase inhibitors (everolimus, sunitinib)17,18 
and peptide receptor radionuclide therapy (PRRT)19. Theoretically, one or 
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more of these treatment options could serve as adjuvant therapy in patients 
with a risk of recurrent disease after curative resection. Clinical trials are 
needed to evaluate this benefit. However, it is difficult to identify high-risk 
patients, most likely explaining why this has never been investigated before.  
 
Until now, it is unclear which combination of risk factors for recurrence matter 
most in patients with grade 1 or 2 NF-pNETs in daily practice. A recent study 
by Birnbaum et al reported tumor size and tumor grade to be independent 
predictors for recurrence in patients with sporadic NF-pNET without distant 
metastases20. However, studies on predictive factors are scarce and 
frequently include patients with either distant metastasis present during 
surgical resection, hereditary syndromes or high-grade carcinoma. The aim 
of this study was to analyze the long-term outcome in a very selective group 
of patients with low- to intermediate-grade NF-pNET without hereditary 
syndromes, grade 3 tumors or distant metastasis at time of diagnosis. 
Recurrence rates and significant predictors for recurrence were analyzed. 
With these predictors, the recurrence-score was developed to calculate the 
risk of recurrence of the individual patient and to identify high-risk patients 
after curative resection.   
 
 
METHODS 
 
Retrospectively, all NF-pNET with a curative resection from 1992 to 2015 of 
three academic institutions were included:  the Erasmus Medical Center in 
Rotterdam and the Academic Medical Center in Amsterdam, both in the 
Netherlands, and the Ospedale San Raffaele in Milano, Italy. All institutions 
are high volume centers for pancreatic surgery and specialized in the 
treatment of neuroendocrine tumors. The pathology reports of all pancreas 
resections in the selected period were reviewed for the diagnosis of pNET. 
Patients were included if a histopathology proven pNET was present. 
Inclusion criteria for this study were adults with a curative resected grade 1 
or 2 NF-pNET without distant metastases at the time of diagnosis. Patients 
with ampullary or duodenal NETs and all patients with (unresectable) locally 
advanced disease or distant metastases, successfully treated or not, were 
excluded.  Patients with hereditary syndromes, such as Multiple Endocrine 
Neoplasia type 1 (MEN-1) or Von Hippel-Lindau syndrome (VHL) or with 
grade 3 NF-pNET, even if diagnosed after resection of the pNET, were also 
excluded.  
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NF-pNET was defined as a pNET without clinical syndrome based on 
symptoms associated with hormone overproduction.  The medical records, 
radiological imaging reports and operation reports were reviewed for the 
demographics and clinical data including, age of surgery, sex, tumor size 
(based on preoperative radiological imaging), tumor location and type of 
surgery. Radiological imaging consisted of abdominal CT scan and in some 
patients of endoscopic ultrasonography and/or octreotide scintigraphy 
(Octreoscan®/68Ga-DOTATATE PET-CT).   
 
Depending on tumor location, pancreatoduodenectomy, distal or total 
pancreatectomy was performed.  Central pancreatectomy or tumor 
enucleation was performed in patients with small pNET far enough from the 
pancreatic duct. Lymphadenectomy was not routinely performed in patients 
with tumor enucleation.  All included NF-pNET were reassessed with 
emphasis on for tumor grade, lymph node involvement, vascular or perineural 
invasion by three experienced pathologists (FJ van K, S van E and JV). Mitotic 
count and histological grade were based on the World Health Organization 
(WHO) classification of 2010 in grade 1 to 321. Resection margins were 
classified according the Royal College of Pathologists22. Completely excised 
tumors were classified as R0, tumors with microscopic margin involvement 
<1mm were classified as R1. Pathology was performed according to the local 
protocols. Major complications after surgery were defined as pancreatic 
fistula grade B/C, delayed gastric emptying grade B/C or post-operative 
bleeding grade B/C, scored according to the ISGPF classifications23-25.  
 
Since small pNET may show a more indolent recurrence pattern, separate 
analyses were performed concerning patient with NF-pNET <2cm. 
 
Besides routine control of physical symptoms, the follow-up program 
consisted of physical examination, laboratory tests and radiological imaging. 
The first year after surgery, patients were seen every 6 months. Thereafter, 
follow-up was annually or in case of elevated chromogranin A or dubious 
radiology results continued every 6 months. Follow-up was indicated for 10 
years after surgery. Recurrence was defined as local recurrence in the 
pancreas, new localization in lymph nodes or the development of distant 
metastases. Recurrence free survival was defined as the percentage of 
patients without recurrence after resection. Disease specific survival was the 
percentage of patients who have not died due to pNET. 
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Statistical analysis 
Statistical analyses were performed using IBM SPSS statistics 20 and R for 
windows version 3.0.2 (cran-Rproject.org). Based on the distribution, the 
data was described with mean and standard deviation (SD) or median and 
interquartile range (IQR). For categorical data, the number and proportion (%) 
were displayed. Kaplan-Meier curves were used to determine the median 
time for recurrence and survival. To identify predictors for survival within 10 
years after curative surgery a Cox proportional hazard regression was 
performed.  This was repeated for predictors for recurrence within 5-years. 
The assumption of proportional hazard regression was tested by visually 
inspecting the log minus log plots. No violations were detected for any of the 
variables included in the model. The results were presented with the Hazard 
Ratio (HR) and the 95% confidence interval (CI95%). To determine predictors 
for recurrence a backwards selection with a P-value of <0.05 was used to 
select the variables one by one from the multivariable Cox regression 
analysis. Based on the hazard ratios of the significant predictors of the 
multivariable Cox regression, a scoring system was made. The hazard ratio 
was translated into a score (the recurrence-score) for each predictor and 
were multiplied by 10 to prevent loss of information due to rounding. The 
overall recurrence-score corresponds to the risk for recurrence within 5 years 
after a curative resection. ROC analysis was performed to determine the most 
suitable cut-off of the recurrence-score. Both the Youden’s index as well as 
the Log Rank method was used to determine the recurrence-score with the 
most appropriate sensitivity and specificity. Model performance was 
assessed by measurements of discrimination and calibration. Discrimination 
is the ability to separate the persons who will have recurrence from the 
persons who will not have recurrence. Calibration is the ability to correctly 
quantify the observed absolute risk. The discriminative ability of the model 
was examined by calculating Harrel’s c-statistic26 with 95% CI and the 
calibration of the model was assessed by calculating the goodness of fit 
Hosmer–Lemeshow Chi-square test. Moreover, we examined the 
discrimination of the WHO grade model and compared the c-statistics of the 
two models using a z-test. The c-statistic may vary from 0.5 to 1.0. A 
discriminative value of 0.5 was considered as good as chance and a value 
above 0.9 was excellent. Calibration was not significant; the prediction of the 
model was comparable with the actual outcome. A 2-sided p-value < 0.05 
was considered significant. The Medical Ethics Review Committee has 
approved the study.  
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RESULTS 
 
With a mean age of 60 years (range 19 – 83) at diagnosis, 211 patients were 
included in the analysis. Patient and tumor characteristics are listed in Table 
1. In total, 139 patients had a G1 tumor. Median tumor size was 25mm (IQR 
15 – 44) and most frequently located in the pancreatic head (40%). 
Pancreatoduodenectomy was performed in 64 (30%), left pancreatectomy in 
101 (48%), tumor enucleation in 29 (14%), central pancreatectomy in 11 (5%) 
and total pancreatectomy in 5 (2%) patients. Postoperatively, major 
complications were seen in 58 patients (27%) and consisted of pancreatic 
fistula grade B/C in 46 patients (22%), delayed gastric emptying grade B/C 
in 7 patients (3%) and postoperative bleeding grade B/C in 2 patients (1%). 
One patient experienced a pancreatic fistula and postoperative bleeding. 
Complete resection (R0) was performed in 179 patients (85%), whereas the 
remaining 32 (15%) showed either microscopic tumor cells at the resection 
margin or within 1 mm (R1). R1 resections were found in 12 (18.8%) patients 
who underwent pancreatoduodenectomy, 8 (7.9%) patients who underwent 
left pancreatectomy, 6 (20.7%) patients who underwent enucleation, 4 
(36.4%) patients with central pancreatectomy and 2 (40%) with a total 
pancreatectomy. 
 
Long-term follow-up 
Median follow-up time was 51 months (IQR 29-72). Recurrence was seen in 
35 patients (17%): 16 (46%) after pancreatoduodenectomy, 14 (40%) after 
left pancreatectomy, 3 (9%) after enucleation, one after central 
pancreatectomy and one after total pancreatectomy. In 24 patients (69%) the 
recurrence was located in the pancreatic remnant, whereas 5 patients (14%) 
developed recurrence as distant metastases and one had lymph node 
metastasis. Mean tumor size of patients with recurrence was 36.8mm versus 
32.9mm for patients without recurrence (p>0.05). Grade 1 was seen in 11 
(31.4%) patients and grade 2 in 24 (68.6%) patients. Ten (28.6%) patients 
with recurrence had R1 resection and 20 (57.1%) had lymph node 
metastases in the resected specimen of the initial surgery. Median time to 
recurrence was 43 months (IQR 23 – 62). Mean survival of patients without 
recurrence was 163 months, compared to 139 months for patients with 
recurrence (p=0.011), Figure 1.  Overall, 19 patients (9%) deceased, including 
9 patients due to tumor progression. The 5- and 10-year disease specific 
survival was 98% and 84%, respectively. Overall survival was 91% within 5 
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years and 68% within 10 years. Recurrence free survival of all patients is 
presented in Figure 1.  
 
Table 1 - Patient and tumor characteristics (n=211), n (%) 
 
Age, median 
 
60 (IQR 50 – 66) 
Male 103 (48.8%) 
Tumor location,  
Head 
Body 
Tail 
 
80 (37.9%) 
59 (28%) 
72 (34.1%) 
Tumor grade 
G1 
G2  
 
139 (65.9%) 
72 (34.1%) 
Tumor size, median 25 mm (IQR 15 – 44) 
 Major complications 58 (26.5%) 
Resection margin 
R0 
R1 
 
179 (84.8%) 
32 (15.2%) 
Positive lymph nodes 51 (24.2%) 
Perineural invasion 28 (13.3%) 
Vascular invasion 50 (23.7) 
Mortality 
Disease related deaths 
19 (9%) 
9 (4.3%) 
Tumors <2cm 
Size, median 
G2 
R1 resection margin 
Positive lymph nodes 
Recurrence 
Mortality 
84 (39.8%) 
14 (IQR 11-17) 
14 (16.7%) 
11 (13.1%) 
10 (11.9%) 
4 (4.8%) 
7 (8.3%) 
Recurrence 
G2 
R1 resection margin 
Positive lymph nodes 
Local recurrence 
< 5 years after surgery 
35 (16.6%) 
24 (68.6%) 
10 (28.6%) 
20 (57.1%) 
24 (68.6%) 
32 (91.4%) 
 
 
IQR: interquartile range 
 
 
Tumor size <2cm 
Based on the latest ENETS guidelines, a sub-analysis for tumors <2cm was 
performed. In this cohort, 84 of the 211 patients had a tumor smaller than 2 
cm. Thirty-seven patients were male (44%) and 47 females (56%), with a 
median tumor size of 14mm. Tumor location was equally distributed between 
the head, corpus and tail of the pancreas (28.6%, 36.9% and 34.5% 
respectively). Enucleations were performed in 23 cases (27.4%), the 
remaining 51 patients underwent pancreatic resection. Eleven patients had a 
R1 resection (13.1%) and 14 patients had a grade 2 tumor (16.7%). Lymph 
node metastases were present in 10 patients (11.9%) and perineural invasion 
was seen in 8 patients (9.5%). Recurrence was seen in 4/84 patients (4.8%).  
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Figure 1 - Kaplan-Meier analysis of patients with a grade 1 or 2 NF-pNET. A Ten-year overall 
survival of patients with and without recurrent disease. B Ten-year recurrence-free survival of all 
patients. 
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Seven patients died, of which 2 were related to pNET. From univariable 
analysis, tumor grade (HR 18.5, CI95% 1.91-179.13, p=0.012), positive lymph 
nodes in the resected specimen (HR 7.8, CI95% 1.09-55.16, p=0.041), 
perineural invasion (HR 30.7, CI95% 3.19-295.74, p=0.003) and vascular 
invasion (HR 6.9, CI95% 0.97-49.03, p=0.05) were predictors of recurrence 
within 5 year after curative surgery. Multivariable analysis was not performed 
due to patient numbers. Disease specific survival was 97% in 5 years and the 
same for 10 years. The 5- and 10-year overall-survival was 91% and 79% 
respectively. 
 
Predictors for survival and recurrence 
A Cox regression analysis was performed to identify risk factors for mortality 
within 10 years after surgery (Table 2). pNET related death was associated 
with perineural invasion (HR 3.8 CI95% 1.51-9.63) and recurrence (HR 2.7, 
CI95% 1.4-6.56). Cox regression analysis was repeated for predictors for 
recurrence within 5 years after surgery (Table 3). Univariable analysis was 
significant for tumor size, R1 resection, tumor grade, positive lymph nodes in 
the resected specimen and perineural invasion. With a backwards selection, 
tumor grade (HR 4.07, CI95% 1.87-8.84), positive lymph nodes in the 
resected specimen (HR 2.44, CI95% 1.17-5.09) and perineural invasion 
(HR2.38, CI95% 1.11-5.10) were significant to predict recurrence in the 
multivariable analysis. Recurrence within five years after curative resection 
was seen in 25% of patients with only tumor grade 2, in 30% of patients with 
only positive lymph nodes and in 14% of patients with perineural invasion. In 
the presence of two predictive factors recurrence was seen in 38% of 
patients with a grade 2 tumor and positive lymph nodes, 40% of patients with 
positive lymph nodes and perineural invasion, and in 33% of patients with a 
grade 2 tumors and perineural invasion. When all predictive factors were 
present 60% of the patients showed recurrence. Of the 107 patients with 
none of these factors present, only 2 developed recurrent disease. 
 
The recurrence-score 
A scoring system was made based on the independent predictors from the 
multivariable Cox regression analysis (Figure 2). The recurrence-score 
predicts the probability to develop recurrence within 5 years after curative 
resection in patients with a grade 1 or 2 NF-pNET. For each patient, a total 
recurrence-score was calculated based on the presence or absence of these 
factors. Patients with recurrent disease showed significantly higher 
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recurrence-scores (49.3) compared to the recurrence-scores of patients 
without recurrence (17.7, p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - The recurrence score to predict recurrent disease within 5 years after curative 
resection. Patients score points for the presence or absence of each of the tumor characteristics. 
The total points can be translated into the probability of recurrent disease within 5 years after 
curative surgery. 
 
 
 
	
	
	
	
	
	
	
	
igure 3 - ROC analysis of recurrence scores to determine the most appropriate cut-off to 
identify high-risk patients for recurrence within 5 years after curative surgery.  
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The recurrence-score was internally validated. The discriminative ability of 
the recurrence-score was good, with a Harrel’s c-statistic of 0.81 (CI95% 
0.75-0.87) and a Hosmer Lemeshow chi-square test of 11.25 (p=0.258). In 
practice, the WHO grading is used to predict recurrence15. The 
discrimination of the WHO grading was lower compared to the recurrence-
score with a c-statistic of 0.72 (CI95% 0.64-0.79). However close, this was 
not significant (p-value=0.059). Calibration of this model was not examined 
because it only consists of two variables, grade 1 and grade 2.  
 
To determine the appropriate cut-off to identify high-risk patients for 
recurrence within 5 years after surgery, an ROC analysis of the recurrence-
score was performed, Figure 3. This resulted in an optimal recurrence-score 
cut-off of 24, with a sensitivity of 91% and specificity of 62%. Kaplan-Meier 
analysis showed a significant difference in recurrence within 5 years after 
surgery for patients with a recurrence-score below 24 with a mean time to 
recurrence of 59 months, compared to patients with a recurrence-score of 
24 and higher and mean time to recurrence of 46.9 months (p<0.001). Mean 
10-year disease specific and overall survival was 181.3 months (CI95% 178.0 
– 184.6) and 110.3 months (CI95% 103.4 – 117.3) respectively for patients 
with a recurrence-score below 24, compared to 167.0 months (CI95% 140 – 
193.6) and 99.4 months (CI95% 90.3 – 108.6) respectively for patients with a 
recurrence-score of 24 and higher (DSS p=0.008, OS p=0.038).  
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Table 2 - Predictors for mortality within 10 years 
Risk factors Univariable Cox Regression Multivariable Cox Regression 
 HR CI95% p-value HR CI95% p-value 
 
Male gender 
 
1.218 
 
0.515 – 2.877 
 
0.654    
Age  
 <40 
 40-50 
 51-60 
 61-70 
 >70 
 
ref 
0.307 
1.276 
1.949 
2.300 
 
ref 
0.019 – 4.919 
0.153 – 10.610 
0.247 – 15.412 
0.256 – 20.624 
 
ref 
0.404 
0.822 
0.527 
0.457 
   
Tumor location 
 Head 
 Body 
 Tail 
 
ref 
0.684 
0.629 
 
ref 
0.248 – 1.884 
0.214 – 1.846 
 
ref 
0.463 
0.399 
   
Tumor size 
 <2cm 
 2-4cm 
 >4cm 
 
ref 
1.249 
1.088 
 
ref 
0.464 – 3.361 
0.345 – 3.431 
 
ref 
0.659 
0.885 
   
Major complication 0.660 0.244 – 1.787 0.414    
R1 resection  2.439 0.980 – 6.072 0.055    
Tumor grade 2 1.816 0.768 – 4.291 0.174    
Positive lymph nodes 2.105 0.872 – 5.085 0.098    
Perineural invasion 4.130 1.644 – 10.375 0.003 3.813 1.510 – 9.627 0.005 
Vascular invasion 1.755 0.723 – 4.263 0.214    
Recurrence 2.977 1.237 – 7.169 0.015 2.730 1.137 – 6.554 0.025 
 
HR: hazard rate, CI: confidence interval, ref: reference 
Table 3 – Predictors for recurrence within 5 years 
Risk factors Univariable Cox Regression Multivariable Cox Regression 
 HR CI95% p-value HR CI95% p-value 
 
Male gender 
 
1.149 
 
0.573 – 2.3 
 
0.696    
Age  
<40 
40-50 
51-60 
61-70 
>70 
 
ref 
0.249 
0.775 
0.830 
0.294 
 
ref 
0.05 – 1.236 
0.213 – 2.818 
0.238 – 2.891 
0.049 – 1.763 
 
ref 
0.089 
0.699 
0.769 
0.181 
   
Tumor location 
Head 
Body 
Tail 
 
ref 
1.969 
1.099 
 
ref 
0.842 – 4.605 
0.412 – 2.929 
 
ref 
0.118 
0.851 
   
Tumor size 
<2cm 
2-4cm 
>4cm 
 
ref 
3.957 
5.920 
 
ref 
1.302 – 12.028 
1.946 – 18.008 
 
ref 
0.015 
0.002 
 
- 
 
- 
 
- 
Major complication 0.932 0.531 – 1.636 0.806    
R1 resection  2.722 1.286 – 5.763 0.009 - - - 
Tumor grade 2 5.625 2.653 – 11.927 <0.001 4.066 1.871 – 8.835 <0.001 
Positive lymph nodes 4.039 2.014 – 8.102 <0.001 2.439 1.170 – 5.085 0.017 
Perineural invasion 4.088 1.970 – 8.485 <0.001 2.380 1.111 – 5.097 0.026 
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DISCUSSION 
 
Patients with pancreatic neuroendocrine tumors generally have a favorable 
prognosis. However, in case of recurrence, these patients have a poor 
survival. Assessment of risk factors for recurrence could therefore be of 
importance. In this study the recurrence-score is presented that can identify 
patients at risk to develop recurrence within 5 years after curative surgery of 
a grade 1 or grade 2 NF-pNET. For these patients adjuvant therapy after 
curative resection might improve prognostic outcomes. For these patients, 
postoperative follow-up regimens can be customized based on their risk 
profile. Further research is warranted to investigate if adjuvant therapy after 
curative resection might improve prognostic outcomes.  
 
The recurrence-score can be calculated from the presented scoring-system 
based on the presence or absence of predictors for recurrence. The 
predictors presented in this study correspond to the ones reported in the 
literature and can be translated into a probability to develop recurrence20,27-
29. With the recurrence-score, a selection of patients who have a high or low 
risk for recurrence after curative resection can be made. For example, 
patients with a recurrence-score of 0 have a 7% risk of recurrence within 5 
years. Cost-effectiveness of follow-up with imaging should be evaluated for 
this group of patients. On the other hand, patients with a recurrence-score of 
40 or higher have a 25% or more risk of recurrence, which will be a clear 
indication for follow-up with imaging techniques and possibly even adjuvant 
treatment to reduce this recurrence risk. To our knowledge, no literature 
exists that describes the role and effects of adjuvant therapy for patients after 
curative surgery of pNET. Based on the treatment of patients with advanced 
pNET, different treatment options are available that can serve as adjuvant 
treatment30. The presented recurrence-score sets a basis for future trials to 
select patients to investigate the role of adjuvant therapy based on risk 
stratification for recurrent pNET. 
 
According to the new ENETS guidelines, patients with NF-pNET smaller than 
2cm of size no longer have to undergo surgery to achieve optimal oncologic 
outcomes. Evidence for these changes in the management of this disease is 
based on retrospective analyses only31-33. Prospective cohorts are necessary 
to confirm this assumption. Theoretically, the same strategy could be 
translated to low-risk patients without unfavorable characteristics after 
surgical resection of pNET. 
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In this cohort, the recurrence-score was a better predictor of recurrence 
within 5 years compared to tumor grade of the WHO classification, with an 
almost statistically significant lower c-statistic of 0.72 (p=0.058). This effect 
may be explained by the comparison of a model with two extra independent 
predictors in comparison with one in the model of the WHO. However, in the 
recurrence-score grading is the strongest independent predictor with a 
hazard ratio of 4.01. 
 
Most studies on risk factors for recurrence after resection of pNET include 
patients with distant metastases present at resection, functional and non-
functional tumors combined or patients with familial syndromes28,34-36. By 
including all these patients, the results are difficult to interpret and sometimes 
misleading since the risk of recurrence and survival is different for these 
patients. In this study, a very selective group of NF-pNET was included and 
analyzed on risk factors for recurrent disease. These strict criteria limit the 
amount of patients suitable for inclusion considerably. To overcome this 
problem, cohorts from experienced international academic centers with close 
relations to the European Neuroendocrine Tumor Society (ENETS) were 
combined to increase the sample size and therefore reliability of the 
recurrence-score. However, the same limitations were experienced in finding 
an adequate validation cohort. External validation is needed in order to 
investigate whether the recurrence-score is useful in another population. 
Because the relevance of the recurrence-score can be of clinical value, we 
have decided to publish these data while external validation is ongoing. 
 
The majority of the patients in this study showed recurrence located in the 
pancreatic remnants (69%) as opposed to distant metastases. In the 
literature, there is inconsistency on the definition of recurrence. Some studies 
only score recurrence when it is diagnosed as distant metastases20,37,38, 
whereas new localization of tumor tissue in the remnant pancreas or regional 
lymph nodes should also be considered as recurrence. In addition, it is not 
yet known if recurrence occurs more frequently locally or as distant 
metastases. Therefore, it is unclear whether these results are influenced by 
selection bias.  
 
There are some limitations in this study. First is the extended inclusion period. 
In the beginning of the study, the follow-up program was not standardized 
for every patient. For example, in patients with elevated chromogranin A, 
radiological imaging was more frequently performed. On the other hand, in 
patients with a grade 1 tumor without positive lymph nodes, a less strict 
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follow-up program was followed. This may bias the time to detect recurrence. 
However, until now there is no exact follow up program in the guidelines4,10,39. 
Furthermore, it has been a challenge to obtain a cohort of this size. An 
unrealistic large cohort is needed to meet up to the standard 
recommendations for Cox regression analysis. Since this study investigated 
a rare disease with a recurrence rate that corresponds to the literature, Cox 
regression analysis has been performed nevertheless and three predictors 
have been included in the recurrence-score1-3.  
 
In this cohort of 211 NF-pNET patients, microscopic positive resection 
margins were seen in 15% after pancreatic resection. Similar results have 
been reported in studies with comparable patient populations38,40. However, 
it is noteworthy that in this cohort incomplete resections were seen in 17.4% 
of the patients that underwent a surgical resection before 2012, whereas this 
was 8.9% from 2012-2015. The proportion of patients with an incomplete 
resection might therefore be explained by the period in which they underwent 
surgery. In previous years it was generally assumed that oncologic outcome 
was not affected by positive resection margins, due to the indolent nature of 
pNET. Even in the present-day, the role of resection margins remains unclear. 
Without this knowledge, surgeons balance the risk of postoperative 
complications against the prognostic value of an extensive resection.  
 
Our future goal in the treatment of grade 1 or 2 NF-pNET is adjuvant 
treatment for high-risk patients with NF-pNET based on the recurrence-
score. External validation with a different cohort is needed in order to 
investigate whether this scoring system is valid for worldwide use. 
Furthermore, clinical trials are needed to investigate if these high-risk patients 
may benefit from adjuvant treatment after curative resection. It is beyond the 
topic of this study to discuss the most optimal design for future research. 
 
In conclusion 
Tumor grade, positive lymph nodes and perineural invasion are independent 
predictors for tumor recurrence. Based on these risk factors, the recurrence-
score is presented to predict recurrence after surgical resection of grade 1 
and 2 NF-pNETs. External validation is required to investigate whether this 
scoring system can be used in the clinical practice. Patients with a 
recurrence-score ≥ 24 are considered to be high-risk and may benefit from 
adjuvant therapy.   
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ABSTRACT 
 
Background. Despite evidence of different malignant potentials, 
postoperative follow-up assessment is similar for G1 and G2 pancreatic 
neuroendocrine tumors (pNET) and adjuvant treatment currently is not 
indicated. This study investigated the role of Ki67 with regard to recurrence 
and survival after curative resection of pNET. 
 
Methods. Patients with resected non-functioning pNET diagnosed between 
1992 and 2016 from three institutions were retrospectively analyzed. Patients 
who had G1 or G2 tumor without distant metastases or hereditary syndromes 
were included in the study. The patients were re-categorized into Ki67 0–5% 
and Ki67 6–20%. Cox regression analysis with log-rank testing for recurrence 
and survival was performed. 
 
Results. The study enrolled 241 patients (86%) with Ki67 0–5% and 39 
patients (14%) with Ki67 6–20%. Recurrence was seen in 34 patients (14%) 
with Ki67 0–5% after a median period of 34 months and in 16 patients (41%) 
with Ki67 6–20% after a median period of 16 months (p<0.001). The 5-year 
recurrence-free and 10-year disease-specific survival periods were 
respectively 90 and 91% for Ki67 0–5% and respectively 55 and 26% for Ki67 
6–20% (p<0.001). The overall survival period after recurrence was 44.9 
months, which was comparable between the two groups (p = 0.283). In 
addition to a Ki67 rate higher than 5%, tumor larger than 4 cm and lymph 
node metastases were independently associated with recurrence. 
 
Conclusion. Patients at high risk for recurrence after curative resection of G1 
or G2 pNET can be identified by a Ki67 rate higher than 5%. These patients 
should be more closely monitored postoperatively to detect recurrence early 
and might benefit from adjuvant treatment. A clear postoperative follow-up 
regimen is proposed. 
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INTRODUCTION 
 
One of the concerns for patients with pancreatic neuroendocrine tumors 
(pNET) is the accurate prediction of clinical outcome. Tumor stage and grade 
have proved to be useful in estimating disease course and have been 
confirmed repeatedly in valuable studies1–6. Despite this, follow-up 
assessment is the same for all patients who have undergone curative 
resection of pNET. Neither surveillance protocols nor adjuvant treatment 
options based on expected recurrence rates are available, although the 
recurrence rate is reported to be 17% after resection of well-differentiated 
pNET, with considerable consequences for survival7. 
 
The 2010 tumor grade classification of the World Health Organization (WHO) 
divides pNET into three prognostic groups based on the proliferation index 
assessed through the expression of the nuclear antigen Ki67, with Ki67<3% 
classified as low-grade pNET (G1), Ki67 3–20% classified as intermediate-
grade pNET (G2), and Ki67>20% classified as high-grade neuroendocrine 
carcinoma (NEC) (G3)8–11. 
 
Multiple studies have shown a good correlation between the Ki67 index and 
tumor size, angioinvasion, and biologic behavior of neuroendocrine tumors12–
14. However, heterogeneity of pNET is increasingly described, and the wide 
range of the Ki67 distribution in the grading systems is under debate15–17. 
Therefore, WHO proposed an updated classification system for pNET this 
year, in which high-grade tumors with Ki67>20% are subdivided into well-
differentiated G3 NET and poorly differentiated G3 NEC18. Although clear 
upper or lower limits for G3 NET and G3 NEC are not provided, differences 
in genetic basis and the course of disease are suggested19–21. Similar 
assumptions also are apparent for tumors with Ki67<20%. A Ki67 cutoff of 
10% is used to select patients suitable for liver transplantation according to 
the Milan criteria, comparable with the inclusion criteria of the Clarinet study 
and of many oncologists generally when choosing a systemic treatment22,23.  
 
For non-metastasized patients, the latest European Neuroendocrine Tumor 
Society (ENETS) guidelines also discriminate between ‘‘low-G2’’ and ‘‘high-
G2’’ pNET without providing cutoff values, suggesting different treatment 
responses within this patient population1. Furthermore, several studies 
describe a higher discriminating capacity when G1 and G2 pNET are divided 
by a Ki67 cutoff of 5% instead of 3% to predict disease progression5,24,25. 
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After curative surgery of pNET, follow-up assessment is focused on early 
detection of recurrence. The use of the Ki67 proliferation index to guide 
postoperative management has not been described previously7,26,27. Based 
on the capacity of Ki67 to predict disease outcome in general, it is likely that 
the proliferation index of surgically treated pNET could also be predictive in 
estimating the risk for the development of recurrence. Therefore, we 
hypothesized that pNET with Ki67<20% indicates a heterogeneous group of 
tumors with a different postoperative disease course and aimed to investigate 
the role of Ki67 in predicting recurrence and survival after curative resection. 
 
 
METHODS 
 
The study enrolled patients who underwent a curative resection of a non-
functioning pNET with Ki67<20% between 1992 and 2016 from the following 
three academic centers: The Academic Medical Center Amsterdam and The 
Erasmus University Rotterdam in the Netherlands (both ENETS Centers of 
Excellence) and the Ospedale San Raffaele in Milan, Italy. The data for 211 
patients (75%) also have been presented in a previous study of this group7.  
 
All the patients were free of distant metastatic disease at diagnosis and not 
associated with a genetic predisposition for the development of pNET. 
Pathology reports were reviewed for the diagnosis of pNET, and patients 
were included in the study if pNET was histologically proven. All patients with 
(unresectable) locally advanced or distant metastatic disease, successfully 
treated or not, were excluded from the study.  
 
The functional status of the tumors was based on the clinical presentation of 
symptoms associated with hormonal overproduction. The Ki67 proliferation 
index was retrieved from pathology reports. Tumor tissue of patients with a 
diagnosis before 2010 or with pathology reports containing insufficient 
information on the Ki67 index (n = 24) were reassessed with an emphasis on 
Ki67 by experienced pathologists. 
 
For all the patients, visual assessment (‘‘eyeballing’’) was used to assess 
Ki67, and histologic grade was based on the WHO classification of 201028. 
Classification according to the Royal College of Pathologists was used to 
assess resection margins29. Depending on the tumor location, 
pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy 
was performed. Central pancreatectomy or enucleation was performed for 
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patients with a small pNET far enough from the pancreatic duct.  
Lymphadenectomy was not routinely performed with enucleation. 
 
The patients were categorized into groups based on the Ki67 proliferation 
index of the tumor. Because pathologists frequently did not report an exact 
number to indicate Ki67, but rather provided a range for the proliferation rate, 
groups were initially defined by the most commonly used cutoffs provided in 
the pathology reports as follows: G1 (Ki67 0–2%), low G2 (Ki67 3–5%), mid-
G2 (Ki67 6–10%), and high G2 (Ki67 11–20%). Because early Kaplan–Meier 
analysis (Figure 1a) showed similar results for patients with G1 and low G2, 
as well as for patients with mid-G2 and high G2, and because the cutoff of 
5% also was supported by Cox proportional hazard regression (Table 1), the 
patients were re-categorized into two groups: Ki67 0–5 and Ki67 6–20% 
(Figure 1b). 
 
Follow-up assessment after resection consisted of physical exams, 
laboratory tests, and radiologic imaging. The frequency of hospital visits was 
at least every 6 months for the first 2 years and yearly thereafter. Follow-up 
time was defined as the time to the last known date the patient was alive or 
the time until death. Recurrence was defined as local recurrence in the 
pancreas, a new location in lymph nodes, or the development of distant 
metastases. All recurrences were identified through radiologic imaging. 
 
Statistical analyses were performed using IBM SPSS Statistics 23 (IBM 
Corp., Armonk, NY). On the basis of the distribution, the data were described 
using mean and standard deviation (SD) or using median and interquartile 
range (IQR). For categorical data, the number and proportion (%) were 
displayed. Differences between patient and tumor characteristics were 
investigated using a Chi-square statistic for categorical values and a Mann–
Whitney U test for numeric values. 
 
Kaplan–Meier survival analyses with log-rank testing were performed to 
investigate recurrence-free and disease-specific survival. To identify 
variables associated with recurrence within 5 years after surgery, Cox 
proportional hazard regression analyses were performed. Receiver-
operating-characteristic (ROC) analysis with area-under-curve (AUC) 
determination was performed to investigate the diagnostic ability with regard 
to recurrence and disease-specific survival. The results were presented with 
the hazard ratio (HR) and the 95% confidence interval (CI). The discriminative 
ability of the model was examined by calculating the Harrel c-statistic with 
0505 
05.  
	80 
95%.30 Moreover, we examined the discrimination of the WHO grade model 
and compared the c-statistics of the two models using a z test. 
 
The net reclassification improvement (NRI) analysis was used to quantify how 
well our new proposed model reclassified subjects compared with the current 
WHO grading classification31,32. 
 
 
RESULTS 
 
This study analyzed 280 patients. Patient and tumor characteristics are 
presented in Table 2. Left pancreatectomy was performed for 136 patients 
(49%), pancreaticoduodenectomy for 80 patients (29%), enucleation for 45 
patients (16%), central pancreatectomy for 13 patients (5%) and total 
pancreatectomy for 5 patients (2%). Tumors with Ki67 0–5% were seen in 
241 patients, whereas 39 patients had a pNET with Ki67 6–20%. The patients 
with Ki67 6–20% more frequently had lymph node metastases (53 vs 22%; p 
= 0.0002), perineural invasion (28 vs 11%; p = 0.0129), vascular invasion (51 
vs 20%; p < 0.0001), and R1 resection (36 vs 12%; p = 0.0438) than the 
patients with Ki67 0–5%. 
 
Recurrence and Survival 
Recurrence was experienced by 49 patients (18%), and the majority (53%) of 
these recurrences were located in distant organs. The patients with 
recurrence more often had tumors in the pancreatic head (45 vs 36%; p = 
0.0174), tumors larger than 2 cm (86 vs 54%; p < 0.0001), WHO 2010 grade 
2 tumors (47 vs 25% G1; p = 0.0033), R1 resection (26 vs 11%; p=0.0126), 
lymph node metastases (60 vs 19%; p<0.0001), perineural invasion (30 vs 
10%; p = 0.0004), and vascular invasion (49 vs 19%; p = 0.0342) than the 
patients without recurrence. 
 
Of the 241 patients with Ki67 0–5%, 34 (14%) had a recurrence. Local 
recurrence in the pancreas of 12 patients was observed and recurrence in 
the regional lymph nodes of 2 patients. Distant metastases developed in 18 
patients. Of the 39 patients with Ki67 6–20%, 16 (41%) had a recurrence, 
with 1 found locally in the pancreas, 2 found in regional lymph nodes, and 8 
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Figure 1 - Recurrence within 5 years after curative resection. A Patients categorized into four 
groups based on Ki67. B Patients categorized in two groups based on Ki67. 
A 
B 
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found as distant metastases. Kaplan–Meier analysis showed significantly less 
recurrence within 5 years after surgery for the patients with Ki67 0–5% than 
for the patients with Ki67 6–20% (p < 0.001; Figure 1b). The 5-year 
recurrence-free survival rate was 90% for the patients with Ki67 0–5 and 55% 
for the patients with Ki67 6–20%. Overall, the median time to recurrence 
(TTR) was 31.7 months (IQR 10.5–47 months): 34 months (IQR 16–59 months) 
for the patients with Ki67 0–5% and 16 months (IQR 4.25–23.25 months) for 
the patients with Ki67 6–20% (p = 0.005). 
 
The median survival time was 63 months for the patients with Ki67 0–5% 
tumors and 45 months for the patients with Ki67 6–20% tumors (p = 0.017). 
The 10-year disease-specific survival was 91% for the patients with Ki67 0–
5% tumors and 26% for the patients with Ki67 6–20% tumors (p < 0.001, 
Figure 2). The median survival time after recurrence was 44.9 months (IQR 
16–68.3 months), which was statistically comparable between the two 
groups (p = 0.283). 
Table 1 - Predictors for recurrence within 5 years (N=280) 
Risk factors Univariate Cox regression Multivariable Cox regression 
 HR 95%CI P value HR 95%CI P value 
 
Male sex 
 
0.99 
 
0.49 – 2.00 
 
0.976    
Age 
<40 
41-50 
51-60 
61-70 
>70 
 
ref 
0.72 
0.86 
1.06 
0.20 
 
ref 
0.18 – 2.88 
0.23 – 3.26 
0.30 – 3.74 
0.02 – 1.95 
 
ref 
0.639 
0.826 
0.923 
0.167 
   
Tumor location 
Head 
Body 
Tail 
 
Ref 
0.86 
0.85 
 
Ref 
0.36 – 2.05 
0.37 – 1.97 
 
Ref 
0.738 
0.704 
   
Tumor size (mm) 
<20 
21-40 
>41 
 
ref 
2.45 
6.13 
 
ref 
0.84 – 7.16 
2.24 – 16.75 
 
ref 
0.102 
<0.001 
 
 
 
2.27 
 
 
 
1.10 – 4.72 
 
 
 
0.027 
R1 resection 1.72 0.71 – 4.19 0.233    
WHO Tumor grade 0.24 0.12 – 0.47 <0.001 - - - 
Ki67 (%) 
0-2 
3-5 
6-10 
11-20 
 
ref 
1.99 
5.88 
7.68 
 
ref 
0.72 – 5.52 
2.46 – 14.05 
2.52 – 23.42 
 
ref 
0.188 
<0.001 
<0.001 
   
 
Ki67 >5% 
 
5.54 
 
2.68 – 11.43 
 
<0.001 
 
5.21 
 
1.47 – 18.4 
 
0.010 
Positive lymph nodes 4.95 2.32 – 10.58 <0.001 3.36 1.48 – 7.61 0.004 
Perineural invasion 3.17 1.41 – 7.17 0.005 - - - 
Vascular invasion 3.09 1.50 – 6.37 0.002 - - - 
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Table 2 - Tumor and patient characteristics (N=280) 
 
Male : Female 
 
136 : 144 
Age Median 59 years (IQR 48.8 – 66) 
Follow-up Median 62 months (IQR 36– 84) 
Tumor location 
   Head 
   Body 
   Tail 
 
   105 (38%) 
   81 (29%) 
   94 (34%) 
Ki67 (%) 
   0-2 
   3-5 
   6-10 
   11-20 
Mean 2.8 (SD = 3.7) 
   199 (71%) 
   42 (15%) 
   28 (10%) 
   11 (4%) 
Tumor size 
   <20mm 
   21-40mm 
   >40mm 
Median 25mm (IQR 15 – 40) 
   113 (40%) 
   100 (36%) 
   67 (24%) 
R0 : R1 240 : 39 
Lymph node metastases 65 (23%) 
   Missing: 12% 
Perineural invasion 34 (13%) 
   Missing: 9% 
Vascular invasion 65 (25%) 
   Missing: 5% 
Recurrence 
   Local 
   Regional 
   Distant 
   Unknown location 
 
   Size 
   Ki67 
   G2* 
   R1 resection 
   Lymph node metastases 
   Perineural invasion 
   Vascular invasion 
49 (18%) 
   12 (25%) 
   4 (8%) 
   26 (53%) 
   7 (14%) 
 
   Median 40mm (IQR 25-59) 
   Mean 4.8% (SD = 5.4) 
   23/49 (47%) 
   13/49 (27%) 
   27/49 (55%) 
   13/49 (27%) 
   23/49 (47%) 
Time to recurrence Median 31.7 months (IQR 10.5 – 47) 
Survival after recurrence Median 44.9 months (IQR 16 – 68.3) 
>30-day mortality 
   Disease related deaths 
25 (9%) 
   14 (5%) 
 
* According to the 2010 WHO classification (Klimstra et al. 2010) 
 
 
The ROC analysis for Ki67 showed an AUC of 0.683 for the prediction of 
recurrence within 5 years. The highest sensitivity and specificity were 
reached at a Ki67 cutoff value of 5%, with a sensitivity of 37% and a 
specificity of 87%. An AUC of 0.737 was found for 10-year disease-specific 
survival. 
 
The discriminative ability of this Ki67 model showed a Harrel c-statistic of 
0.672 (95% CI 0.591–0.753). The discrimination of the WHO grading with 
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regard to predicting recurrence was comparable, with a c-statistic of 0.681 
(95% CI 0.602–0.760). This was not statistically significant (p = 0.781). 
 
Net Reclassification Improvement Analysis 
Table 3 presents the results of the NRI analysis. The additive NRI of the 
proposed Ki67 cutoff value was 0.866, indicating that the new cutoff value 
had good additive value for the WHO grading classification. The absolute NRI 
was 10%, indicating that 10% of patients were correctly reclassified in our 
proposed model based on their risk for the development of recurrence within 
5 years. This effect can best be attributed to the reclassification of patients 
with a low risk for the development of recurrence. 
 
Cox Proportional Hazard Analysis 
The factors related to recurrence within 5 years after surgery from the 
univariable Cox regression analyses were tumor size greater than 4 cm, WHO 
tumor grade, Ki67>5%, lymph node metastases, and perineural and vascular 
invasion. The independent predictors for recurrence were tumor size greater 
than 4 cm (HR 2.5; 95% CI 1.14–5.40), Ki67>5% (HR 3.0; 95% CI 1.34–6.81), 
and lymph node metastases (HR 3.3; 95% CI 1.40–7.70) (Table 1). Tumors 
larger than 4 cm were seen in 67 patients, 21 (31%) of whom experienced a 
recurrence. The absolute NRI of Ki67 compared with size was 6.5%. Lymph 
node metastases were present in 65 patients, 27 of whom experienced 
recurrence (42%). The absolute NRI of Ki67 compared with lymph node 
metastases was 5%. 
 
 
 
Table 3 – Reclassification among patients with and without recurrence 
WHO grading model New proposed Ki67 cut-off 
  Ki67 0-5% 
 
Ki67 6-20% 
 
Total 
 
Patients with recurrence (N=49, 17,5%) 
Grade 1 26 0 26 
Grade 2 7 16 23 
Total 33 16 49 
 
Patients without recurrence (N=231, 82,5%) 
Grade 1 173 0 173 
Grade 2 35 23 58 
Total 208 23 231 
 
Net reclassification of patients with recurrence:  0-7 = -7. Net reclassification of patients without recurrence: 
35-0=35. Additive NRI: ((-7/49) x 100) + ((35/231) x 100) = 0.866. Absolute NRI: ((-7 + 35)/280) x 100) = 10%. 
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Figure 2 - The 10-year disease-specific survival times for patients with Ki67 0–5 and Ki67 6–
20%. 
 
 
The 10-year disease-specific survival was associated with Ki67 >5% and 
perineural invasion in the univariate analysis, but only Ki67 >5% was 
independently associated with 10-year disease specific survival in the 
multivariable Cox regression analysis (HR 6.5; 95% CI 1.93–21.79; p = 0.003). 
 
 
DISCUSSION 
 
We propose a novel categorization of low- and intermediate-grade pNET 
based on the Ki67 index to predict recurrence after curative resection. 
Tumors with Ki67 6–20% have a threefold higher risk for the development of 
recurrence within 5 years and show significantly shorter survival than tumors 
with Ki67 £5%. With this cutoff value, a reliable method for stratifying patients 
into groups of high and low risk for recurrence after surgery is presented. 
 
In a previous study, we presented a scoring system to identify high-risk 
patients through three predictors for recurrence7. The current study 
contributes to strengthening of this scoring system. When the criteria for 
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grade 2 tumors are modified for tumors with Ki67>5%, it will be possible to 
identify high-risk patients more accurately. The recurrence score showed a 
sensitivity of 91% and a specificity of 62% and is expected to increase with 
this revision. Furthermore, patients with Ki67 3–5% (15% of our cohort) will 
be downgraded by this modification, limiting unnecessary treatment or 
monitoring. External validation of the scoring system currently is being 
performed and will include this new Ki67 distribution as well.  
 
Postoperative follow-up assessment of patients with pNET typically consists 
of hospital visits combined with laboratory tests and/or radiologic or nuclear 
imaging. A clear guideline for postoperative management such as the 
frequency of hospital visits, the method for diagnostic testing, or the duration 
of follow-up assessment has not been recommended to date. Combining the 
presented results with preexistent literature, we propose a postoperative 
surveillance protocol based on the risk of recurrence for patients who have 
non-metastasized pNET with K67<20% (Table 4). This scheme comprises 
yearly consultations with imaging for all patients and additional half-yearly 
consultations with clinical assessments and laboratory tests (chromogranin 
A) for high risk-patients. Based on clinical findings and laboratory results, 
additional imaging may be obtained.  
 
Ideally, imaging is alternated between radiologic and somatostatin receptor 
imaging to achieve the highest accuracy. Findings have shown that gallium-
based nuclear imaging has the highest sensitivity and specificity for the 
detection of pNET and is therefore the preferred nuclear imaging method33–
36. Radiologic imaging with either contrast-enhanced computed tomography  
	
	
	
	
Table 4 – Surveillance protocol after curative resection of pNET with Ki76 <20% 
 Yearly follow-up Additional follow-up Frequency Duration 
Low-risk 
patients* 
Clinical 
assessment 
Imaging** 
 
-- Yearly At least 5 
years 
High-risk 
patients* 
Clinical 
assessment 
Imaging** 
Clinical assessment 
Laboratory tests***  
 
Every 6 months 10 years 
 
* Risk stratification either through the newly proposed Ki67 distribution, or more accurately through to the 
modified version of the recurrence score by Genç et al. (Genc et al. 2017a) 
** Alternating between anatomical and nuclear modalities 
*** Chromogranine A  
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(CT) or (diffusion weighted) magnetic resonance imaging (MRI) is advised37–
39. Based on the median time to recurrence, a follow-up period of 10 years is 
encouraged because late recurrences have been described7. The interval 
between assessments can be increased if the disease is stable after 5 years, 
especially for low-risk patients.  
 
Due to the retrospective nature of this study, it was not possible to assess 
exact Ki67 rates for each patient. It is questionable, however, whether exact 
rates for each tumor will be more meaningful in determining postoperative 
prognosis. At this writing, exact Ki67 values have limited clinical relevance 
because the choice for treatment is often determined by tumor grade or 
smaller ranges of Ki67. Furthermore, the proliferation index of a tumor may 
have different prognostic significance in different stages of disease or 
treatment. This is already evident, for example, in determination of systemic 
treatment options for patients with disseminated disease. A Ki67 cutoff of 
10% often is used by oncologists, confirming heterogeneity in malignant 
potential within one WHO grading group. The treatment of localized 
nonfunctioning tumors smaller than 2 cm might also be influenced by 
different Ki67 cutoffs, in which the choice for surgical versus conservative 
treatment may change for G2 tumors with higher or lower Ki67 values. In 
addition, assessing the exact amount of Ki67-positive cells, either manually 
on printed images or determined through computer software, also can create 
a false sense of accuracy because each method for counting positive cells is 
associated with an error margin. Likewise, differences in practice can lead to 
intra- and inter-observer variability. Therefore, it might be both more reliable 
and more feasible to agree on smaller ranges of Ki67 (e.g., <5, 5–10, 15–20%) 
rather than exact values, with stratification of patients into their risk for the 
development of recurrence. 
 
The current results must be seen in light of their limitations. Data were 
evaluated retrospectively, and pathology reports were not standardized at 
the time of treatment. Furthermore, the treatment of recurrence was not taken 
into account when survival was analyzed. Because survival after recurrence 
was comparable between Ki67 0–5 and Ki67 6–20% tumors, we expect the 
treatment of these patients to be similar. Nevertheless, results might be 
biased, and survival after recurrence might show treatment results rather than 
the effect of recurrence itself. In addition, these results could be interpreted 
with the assumption that early detection and treatment of recurrence will 
result in survival benefit. However, no studies support this theory, and 
prospective clinical trials are necessary to confirm these hypotheses. 
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At this writing, the clinical relevance of this study may be limited except for 
de-escalation of follow-up regimens for Ki67 0–5% patients and 
intensification of follow-up regimens for patients with Ki67 6–20%. Adjuvant 
therapy to prevent recurrence in the future could be a possibility. However, 
the vicious circle of nonexistent data, together with the difficulty of obtaining 
prospective studies for this purpose, forms an obstacle to the development 
of such treatments. To overcome these issues, a consensus study has been 
initiated among European pNET experts to discuss possibilities for 
investigating the role of adjuvant treatment for high-risk patients. The results 
of this consensus will be published shortly. The current study might bring us 
one step closer to achieving this necessary research by clarifying the 
selection of patients who should be eligible for adjuvant treatment. 
 
In conclusion, this study is the largest study to describe the use of the Ki67 
proliferation index to estimate postoperative recurrence. These results 
contribute to the assumption of tumor heterogeneity among patients with a 
Ki67<20%. Future studies should focus on determining Ki67 rates, preferably 
in prospective trials, to propose a further alteration of the grading system for 
well-differentiated pNET. 
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ABSTRACT 
 
Background. Recurrence of pancreatic neuroendocrine tumors (pNET) after 
surgery is common. Strategies to detect recurrence have limitations. We 
investigated the role of clinical criteria and the multigene polymerase chain 
reaction–based NETest during post‐operative follow‐up of pNET. 
 
Methods. We studied 3 groups of resections: R0 with no recurrence (n = 11), 
R0 with recurrence (n = 12), and R1 with no recurrence (n = 12). NETest levels 
(>40%) were compared with chromogranin A (CgA) and clinicopathological 
criteria (CC; grade, lymph node metastases, size). Nonparametric, receiver 
operating characteristics, logistic regression, and predictive feature 
importance analyses were performed. 
 
Results. NETest was higher in R0 with recurrence (56 ± 8%) compared with 
R1 with no recurrence (39 ± 6%) and R0 with no recurrence (28 ± 6%, P < 
.005). NETest positively correlated with recurrence (area under the curve: 
0.82), CgA was not (area under the curve: 0.51 ± 0.09). Multiple regression 
analysis defined factor impact as highest for NETest (P < .005) versus CC (P 
< .03) and CgA (P = .23). NETest gave false positive or negative recurrence 
in 18% using a 40% cutoff. Logistic regression modeling of CC was 83% 
accurate; it was 91% when the NETest was included. Combining CC and 
NETest was approximately 2 more effective than individual CC alone 
(increase in R2 value from 43% to 80%). 
 
Conclusion. A multigene blood test facilitates effective identification of pNET 
recurrence, prediction of disease relapse, and outperforms CgA. 
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INTRODUCTION 
 
Although the majority of patients with pancreatic neuroendocrine tumors 
(pNET) are diagnosed at an advanced stage, improvements in imaging 
modalities, awareness of the disease, and pathological recognition have 
contributed to the improvement in detection of localized disease1-3. For 
patients with nonfunctioning pNET 20mm in size without distant metastasis, 
complete surgical resection is recommended as the primary curative 
strategy4,5. Thereafter, effective follow‐up programs are designed to detect 
recurrence at an early stage, given that treatment of limited disease has the 
most favorable outcome6-8. However, data on post‐curative surgical 
recurrence remains limited, making it challenging to determine the best 
follow‐up strategy. In general, recurrence is thought to occur sporadically, 
yet some studies report rates up to 48%.9 Furthermore, recurrence is known 
to be an independent predictor for a poor 10‐year disease‐specific survival10.  
 
A key unmet need in improving outcome is the early detection of recurrent 
disease and the timely initiation of treatment after pNET resection. In many 
cases, early detection of recurrence offers more favorable treatment options, 
sometimes with curative intent, such as resection of the remnant pancreas or 
solitary liver metastases11,12. Liver‐directed, locally ablative procedures are 
recommended for patients with limited, nonresectable tumor burden13-15. 
When recurrence is discovered with an extensive disseminated disease, 
systemic treatment is often the only option16. Despite the variety of treatment 
options, there is uncertainty with regard to the optimal treatment regimen. 
Newly introduced molecular‐based markers, along with clinical trials 
comparing the efficacy of treatment modalities, offer a chance to move the 
treatment of neuroendocrine tumor disease toward personalized patient care. 
Given the multiple treatment options available for NET disease, the early 
detection of recurrence and the judicious introduction of therapy should be 
considered to optimize pNET outcome.  
 
Current guidelines to evaluate tumor recurrence recommend radiological 
examinations and biomarker evaluation during follow‐up4,5. Chromogranin A 
(CgA) used to be considered as the most useful biomarker for detection of 
metastases after curative resection of pNET17. However, its low sensitivity of 
67% and specificity of 68%, as well as controversy regarding technical 
criteria of the assay, have led to a significant diminution in enthusiasm for its 
clinical utility17,18. Overall, the general accuracy of CgA is moderate, given its 
poor metrics as a biomarker and the high false positives noted19-21. Although 
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some reports describe an increased diagnostic accuracy with a high tumor 
load, this is of limited value in an early detection and treatment strategy17,22. 
The limited clinical utility of CgA and the overall lack of efficacy of 
monoanalyte peptide or amine secretory biomarkers has led to considerable 
interest in developing novel and effective tools for the surveillance of 
neoplasia. In this respect, considerable attention has focused on the 
evaluation of the molecular characteristics of cancer and the development of 
sensitive techniques to define the molecular biology of the tumor as opposed 
to measuring its secretory products. The term liquid biopsy has been coined 
to describe the technique of detecting a tumor in blood and has been 
effectively used in other cancers including breast and colon23,24. Recently, a 
liquid biopsy strategy for neuroendocrine tumors has been described25. It 
comprises a multianalyte polymerase chain reaction–based blood test 
specific for neuroendocrine tumors (the NETest) with a sensitivity and 
specificity of >93% for diagnosis. This multianalyte biomarker tool has been 
successfully used to demonstrate residual disease and the early detection of 
recurrent disease after surgical resections in small bowel and lung NETs26,27.  
 
This prospective surgical cohort study aimed to determine the prognostic 
accuracy of neuroendocrine transcript expression in blood, compared with 
CgA and other known clinical criteria associated with pNET recurrence, to 
determine its usefulness as a biomarker for assessment of surgical efficacy 
and detection of recurrence after curative resection. 
 
 
METHODS 
 
Patient selection 
All patients that were operated on for pNET in the Academic Medical Center 
Amsterdam between 2006 and 2015 were screened for inclusion (Figure 1). 
The pathology reports of all pancreatic resections in the selected period were 
reviewed for the diagnosis of pNET. Only patients with histologically 
confirmed diagnosis of pNET were eligible for enrollment to the study. 
Included were 35 patients of 18 years or older and surgically treated for G1 
or G2 localized pNET (per pNET Ki‐67 cutoff classification28) without distant 
metastases or hereditary syndromes at initial diagnosis. The study group 
demographics and clinicopathological characteristics are included in Table 
1. 
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Patients were divided into 3 groups based on the pathological assessment 
of the pancreatic resection margins and the clinical disease status at the time 
of the blood draw. Resection margins were classified according to the Royal 
College of Pathologists. Completely excised tumors were classified as R0, 
whereas tumors with microscopic margin involvement <1 mm were classified 
as R1. Assessment of completeness of surgical resection and disease 
staging at the time of initial diagnosis or during follow‐up was based upon 
anatomical imaging (computed tomography [CT]/magnetic resonance 
imaging [MRI]). Tumor recurrence was defined as local recurrence in the 
remnant pancreas, new localization in lymph nodes (LNs), or the development 
of distant metastases after initially being rendered free of disease, and was 
diagnosed in accordance with RECIST 1.0 criteria.  
 
The 3 groups comprised of: (1) R0 resection and no signs of recurrence 
during follow‐up (R0NR); (2) R0 resection and evidence of recurrent disease 
on imaging during follow‐up (R0R); (3) R1 resection and therefore residual 
tumor in situ, without evidence of recurrence on imaging (R1NR). 
 
 
 
Figure 1 - STARD diagram outlining the study. NETest Low (scores <40%) and NETest High 
(scores >40%). CgA normal: values <108 ng/mL; CgA positive: values >108 ng/mL. CgA, 
chromogranin A; STARD: Standards for Reporting Diagnostic Accuracy 
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The medical records, pathology reports, radiological imaging reports, and 
operation reports were reviewed for the demographics and 
clinicopathological data, including patient’s age at the time of surgery, sex, 
tumor functionality, tumor location within the pancreas, type of surgery, 
tumor size (based on post‐operative pathology), grade, LN involvement, and 
perineural and vascular invasion. Radiological imaging consisted of 
abdominal CT or MRI scans and in some patients, endoscopic 
ultrasonography of the pancreas and/or functional imaging (Octreoscan or 
68Ga‐DOTATATE PET/CT) were performed. Use of proton pump inhibitors 
(PPIs) was determined. A control group of healthy volunteers was included. 
The local Medical Ethics Committee approved the study (protocol number: 
NL50925.018.15). 
 
Sample collection 
Two blood samples per patient were collected according to the local protocol 
of the laboratory in the outpatient clinic of the Academic Medical Center 
Amsterdam. Following informed consent, each patient donated two 5mL 
whole blood samples collected into ethylenediaminetetraacetic acid tubes. 
The blood draw was combined with other regular blood tests performed 
during the follow‐up. After sampling, 1 blood specimen was immediately 
stored at 20°C, whereas the second ethylenediaminetetraacetic acid tube 
was spun at 800 rpm (10 minutes) to separate plasma dedicated for CgA 
measurement by enzyme‐linked immunosorbent assay, as previously 
described.29,30 Thereafter, both samples were stored at 80°C within 2 
hours from blood collection. 
 
NETest blood measurement 
Details of PCR methodology, mathematical analysis, and validation have 
been previously published in detail31-34. In brief, this comprises a 2‐step 
protocol (RNA isolation, complementary DNA production, and PCR) from 
ethylenediaminetetraacetic acid–collected whole blood29,31,32. Target 
transcript levels are normalized and quantified versus a population control31. 
Thereafter, multianalyte algorithm analyses are undertaken. Final gene 
expression results are expressed as an activity index score from 0% to 100% 
based on the integration of the majority vote and summated expression of 5 
gene clusters that include the proliferome, epigenome, growth factor 
signalome, and genes involved in pluripotency33. 
 
06 06 
The NETest to detect recurrence and improve follow‐up of well‐differentiated pNET 
	 99 
CgA enzyme-linked immunsorbent assay 
CgA was measured using the NEOLISATM CgA kit (EuroDiagnostica, Malmo, 
Sweden)35. CgA enzyme‐linked immunosorbent assay normal values were 
108 ng/mL34. 
 
Data analysis 
The primary outcome was obtaining the NETest score of the patients in the 3 
various pNET groups as specified above and the control group. A NETest 
score between 0% and 100% was obtained and a value of >20% was 
considered as a positive test25. Scores ranging between 0% and 20% were 
considered as negative. Previous studies have identified that a cutoff of 40% 
differentiates low activity (stable) disease from active (progressive) 
disease34,36. Therefore, scores ranging between 41% and 100% were 
evaluated as predictive of disease recurrence. Scores for each patient and 
each group were collated and assessed. In addition, CgA levels were 
compared with the NETest score. Data are presented as mean ± standard 
error of mean (median: [interquartile ranges]). 
 
Statistical analysis 
Statistical analysis was performed using SPSS Statistics for Windows version 
23.0 (IBM Corp., Armink, NY), Prism 6.0 for Windows (GraphPad Software, 
La Jolla, CA; www.graphpad.com), and MedCalc Statistical Software version 
12.7.7 (MedCalc Software bvba, Ostend, Belgium; www.medcalc.org; 2013). 
Sensitivity comparisons using Fisher’s exact test, nonparametric tests, and 
receiver operating characteristics analysis were made between the NETest 
and CgA and/or other selected tumor clinicopathological characteristics 
known as predictive for recurrence. The accuracy of each of the variables 
separately was compared with the NETest, as well as in various 
combinations, using receiver operating characteristics curve analyses and 
the sensitivity, specificity and area under the curve (AUC) were calculated. 
Area under the curves were compared and the Z‐statistic (values >1.96 are 
significant) derived and the Youden J index (performance of a diagnostic) was 
calculated. Multiple regression and logistic regression analyses were 
undertaken to identify which parameters were associated with recurrence. 
The odds ratio (OR), 
2 value, and Nagelkerke R2 coefficient (coefficient of 
determination) were derived to assess the strength of the association or 
“relatedness” of each factor or combination of factors to recurrence37. 
Predictive feature importance analysis (FIA) was undertaken to define the 
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“importance value” for each factor (biomarker or clinical criterion) alone or in 
combination. Importance values were derived using a random forest 
approach that evaluates the output from decision tree algorithms used to 
define the relationship of a variable for example, a biomarker, to an output for 
example, recurrence. A random forest model is generated with 10‐fold cross‐
validation and examined to determine mean decreases in the Gini 
coefficient.38 The Gini coefficient provides a measure of how each variable 
contributes to the structure of a random forest plot. Variables that result in 
nodes with higher purity (ie, more accurately model disease recurrence) have 
a higher decrease in Gini coefficient39. As such, the greater the decrease in 
the Gini coefficient, the greater the “Importance” value and better the relation 
to predicting recurrence. Biomarkers (CgA, NETest) and 3 clinical variables 
criteria (tumor grade, size, and LN involvement) were each evaluated to 
determine which factor (or combination of factors) had the highest 
“Importance” value score. 
 
 
RESULTS 
 
Demographics and follow-up 
Patients and tumor characteristics are presented in Table 1. In total, 35 
patients were included: 11 patients with R0NR, 12 patients with R0R, and 12 
patients with R1NR. Duration of follow‐up from surgery to the last hospital 
visit was significantly shorter for patients in the R0NR group compared with 
R0R and R1NR (p<0.002; Figure 2). Three patients died during follow‐up, of 
which 1 death was pNET related. The healthy control group consisted of 6 
male and 5 female volunteers, with a median age of 42 years (interquartile 
range, 32.5‐53.5). 
 
Nineteen (54%) of the 35 patients were using PPIs at the time of blood 
collection; 7/11 (64%) R0NR, 7/12 (58%) R0R, and 5/12 (42%) R1NR. Ten of 
the 12 (83%) with recurrence received therapy to treat the disease relapse. 
This included somatostatin analogs (n=5), chemotherapy (n=2), embolization 
(n=1), metastasectomy (n=1) and peptide receptor radionuclide therapy 
(PRRT) (n=1). Collection of blood samples was either after or during these 
treatments. Two patients did not receive therapy for their recurrence. All 
patients without recurrence did not receive any systemic therapy between 
resection and collection of the blood samples. 
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Table 1 - Patient and tumour characteristics 
 R0 with no Recurrence 
(R0NR) 
(n=11) 
R0 with recurrence 
(R0R) 
(n=12) 
R1 resection with no 
recurrence (R1NR) 
(n=12) 
 
Male: Female 
 
4:7 
 
6:6 
 
6:6 
Age, median (IQR) 63 years (59-65) 62,5 years (61-64) 57 years (50-59.5) 
F:NF 0:11 1:11 5:7 
Tumour location 
 Head 
 Body 
 Tail 
 
6 
0 
5 
 
4 
3 
5 
 
7 
4 
1 
Surgical resection (n) 
 Pancreaticoduodenectomy 
 Central pancreatectomy 
 Left pancreatectomy 
 Total pancreatectomy 
 Enucleation 
 
6 
0 
5 
0 
0 
 
3 
2 
6 
0 
1 
 
1 
3 
2 
0 
6 
Grade 1 
Grade 2 
73% (8/11) 
27% (3/11) 
42% (5/12) 
58% (7/12) 
100% (12/12) 
0% (0/12) 
Tumour size, median (IQR) 20mm (17-53) 45mm (27-63.8) 15mm (7.8-27.5) 
Lymph node metastases 27% (3/11) 75% (9/12) 8% (1/12) 
Perineural invasion 50% (3/6) 67% (4/6) 0% (0/3) 
Vascular invasion 50% (4/8) 91% (10/11) 0% (0/5) 
Follow-up, median (IQR) 31 mo (24-47) 105 mo (54.8-125.3) 92.5 mo (61.8-115.8) 
NETest score (%), median (SD) 27 (6.4) 50 (26) 27 (22)  
CgA level (ng/ml), median (SD)  67 (439) 62 (268) 81 (315) 
Time from surgery to blood collection,  
median (IQR) 
18 mo (1-33) 104 mo (44.3-125.3) 91.5 mo (60-105.8) 
Recurrence 
 Local 
 Regional 
 Distant 
--  
25% (3/12) 
17%% (2/12) 
58% (7/12) 
-- 
Time to recurrence, median (IQR) -- 37.5 mo (26-58.3) -- 
Follow-up after recurrence, median (IQR) -- 50 mo (20.8-94.8) -- 
Time from recurrence to blood 
collection, median (IQR) 
-- 49.5 mo (4.5-93.8) -- 
Time from blood collection to last follow-
up, median (IQR) 
18 mo (6-22) 5.5 mo (0-15) 2.5 mo (0.3-9) 
 
CgA, chromogranin A; IQR, interquartile range; SD, standard deviation; mo, months. 
 
 
Biomarker evaluation in controls and pNET cohorts 
The NETest scores were significantly elevated (56 ± 8%: [50%:28.8‐85.25]) 
in the R0R cohort compared with R0NR (28 ± 2%: [27%:20‐40], p=0.004) 
(Figure 3A). Levels were not significantly different in R0R compared with 
R1NR (39 ± 6%: [27%:27‐40], p=0.08). All pNET cohorts, irrespective of 
recurrence, had higher levels (P < 0.05) than controls (19 ± 5%: [20%:13‐20]). 
CgA levels were not significantly different (P = .062‐0.94) between any of the 
3 pNET cohorts (mean: 205‐244 ng/mL; median 62‐18 ng/mL; Figure 3B). 
Levels were higher in the nonrecurrence (NR) cohorts (p<0.05) than in 
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controls (44 ± 5 [40:32‐56]); however, CgA was not significantly different 
(p=0.14) between R0R and controls. 
 
Correlation between biomarkers and recurrence 
The NETest cutoff of 40%36 determined that the area under receiver 
operating characteristic curve (AUROC) for differentiating recurrence from 
NR was 0.82 ± 0.08, Z‐statistic: 4.19; p<0.0001 (Figure 4).  The Youden index 
(J) was 0.64. Using the upper limit of normal (108 ng/mL) as the cutoff for 
CgA, the AUROC was 0.51 ± 0.09. The Z‐statistic was 0.14 and the Youden 
index (J) of 0.02 are not significant (p=0.88). A comparison of the NETest and 
CgA identified the AUC was significantly better for the former. The difference 
between areas was 0.31 ± 0.14; Z‐statistic: 2.01; p=0.044. 
 
Evaluation of PPIs, tumor burden at recurrence, and biomarker 
NETest levels were not different in those using PPIs (44 ± 6%: [33%:27‐73]) 
compared with nonusers (38 ± 6%: [27%:27‐41]). CgA levels were higher in 
those using PPIs (278 ± 86 ng/mL: [142:55‐451]) compared with nonusers 
(153 ± 69 ng/mL: [55:37‐93]). This did not reach statistical significance 
(p=0.059). 
 
In the R0NR group, CgA was elevated in 3 of 7 (43%) on PPI and in 1 of 4 
(25%) not using a PPI. CgA was therefore elevated by PPI in 43% of surgically 
“cured” patients when it was used.  
 
 
 
Figure 2 - Diagram defining the median times of blood collection, last follow‐up, and recurrence. 
LN, lymph node; R0NR, R0 with no recurrence; R0R, R0 with recurrence; R1NR, R1 resection 
with no recurrence 
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Figure 3 - NETest expression and CgA levels in controls and cohorts. A NETest scores were 
significantly elevated in the R0 resection cohort with recurrence (R0R) compared with the 
resection cohort that did not recur (R0NR). Levels were similar between R0NR and R1 resection 
with no recurrence (R1NR: p=0.08). B CgA levels were not significantly different between any of 
the pNET cohorts irrespective of the presence of recurrence or no recurrence. Mean and 
standard error of mean are indicated. CgA, chromogranin A; pNET, pancreatic neuroendocrine 
tumors. 
 
 
In the R1NR group, CgA was elevated in 3 of 5 (60%) on PPI and in 2 of 7 
(29%, no PPI). This indicates that approximately 17% of all R1NR have a 
“true” elevated CgA level, that is, CgA related to neuroendocrine tumor 
disease. All patients with residual disease had single LN‐positive disease. 
This indicates that an elevated CgA is associated with <20% of lymph node–
positive disease. The NETest was low (but positive >20%) in all R1NR 
patients consistent with accurate disease detection. 
 
In the ROR group, CgA was elevated in 5 of the 7 (71%) on PPI. All who were 
not on PPI (5/5) had normal CgA levels. An evaluation of tumor burden 
identified that 2 patients exhibited a single LN recurrence. One had normal 
CgA, and the other had elevated CgA—both were using PPIs. One had an 
elevated NETest and the other had a low NETest. In 1 patient in which a local 
recurrence was identified, CgA was normal (no PPI); the NETest was 
elevated. In 9 patients who developed a distant metastatic disease, 4 had 
elevated CgA levels. All 4 were on PPIs. The NETest was elevated in 6 of the 
9. Low NETest levels were ascribed to effective SSA use (n=2) and 
streptozotocin/5‐fluorouracil (FU) treatments (n=1) at the time of the blood 
draw. CgA elevation in ROR was therefore related to PPI use. 
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Evaluation of biomarkers and clinical factors as predictors of recurrence 
Multiple regression analysis identified that the following biomarkers and the 
tumor clinicopathological characteristics were associated with recurrence: 
NETest score >40% (p<0.001), tumor grade (p<0.03), positive LNs (p<0.03), 
and tumor size >20mm (p<0.02; Table 2). The R2 coefficient was 0.65, the F‐
ratio was 13.9, and p<0.0001. CgA levels alone had no association with 
recurrence (p=0.23). 
 
Examination of the individual factors identified the NETest was overall 83% 
accurate for disease status (Figure 5A). For clinical criteria, this ranged 
between 69% and 80%. Most factors were strongly associated with no 
recurrence (83%‐91%) except for the tumor size, which was poorly 
associated (57%; 
2: p<0.05 vs. LN positivity and NETest). Normal CgA levels 
were identified in 61% of patients with no recurrence and in 59% of those 
with recurrence (p=1.0). CgA levels were therefore unhelpful in the detection 
of recurrence (p<0.005 vs. all other factors: Fisher’s exact test; 2‐tailed). 
 
The OR for each of the individual factors and recurrence in the regression 
models was CgA: 1.11 (p=NS), grade: 9.3 (p=0.005), LN: 14.3 (p= 0.002), and 
size: 14.3 (p=0.003). The OR for the NETest was 21 (p<0.0001).  
 
Individual 
2 values were CgA: 0.02, grade: 7.8, LN: 11.4, and size: 8.7. The 

2 value for NETest was 13.  
 
 
 
Table 2 - Multiple Regression analysis of NETest, CgA and clinicopathological  
parameters associated with recurrence 
Independent factors Coefficient Std. Error r
partial
 t P VIF 
(Constant) -0.1639      
NETest score 0.4550 0.1208 0.5940 3.765 0.0009 1.168 
Tumour size >20mm 0.3903 0.1459 0.4647 2.676 0.0127 2.001 
Positive lymph nodes 0.3106 0.1292 0.4263 2.403 0.0237 1.528 
Grade (G1 vs. G2) 0.3119 0.1329 0.4181 2.347 0.0268 1.413 
Site of tumour (head 
vs. corpus/tail) 
-0.1392 0.1099 -0.2410 -1.266 0.2166 1.182 
CgA  0.1318 0.1064 0.2361 1.239 0.2264 1.064 
Tumour size >40mm -0.1934 0.1536 -0.2397 -1.259 0.2192 2.219 
Non-functional status 0.1769 0.1537 0.2203 1.151 0.2601 1.314 
LNR -0.7323 0.4464 -0.3795 -1.641 0.1204 2.569 
 
LNR = Lymph Node Ratio = number of positive lymph nodes/all dissected lymph nodes 
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Figure 4 -  Receiver operator curve 
analysis for the identification of 
recurrence. NETest: The AUROC for 
differentiating recurrence from no 
recurrence using NETest was 0.82 ± 0.08; 
95%CI, 0.65‐0.93; p<0.0001. CgA: The 
AUROC for differentiating recurrence 
using CgA (normal versus elevated) was 
0.51 ± 0.09; 95%CI, 0.34‐0.69; p=0.88. 
NETest (red line); chromogranin A (CgA; 
green line). An AUC of 0.5 is indicated by 
the thin diagonal line behind the CgA AUC 
line (green). AUC, area under the curve; 
AUROC, area under the receiver operator 
characteristic 
 
 
 
Nagelkerke R2 (relatedness—coefficient of determination) were CgA: 0.0008, 
grade: 0.27, size: 0.31, and LN: 0.39 (Figure 5B). For the NETest, R2 was 
0.43. 
 
Combining all 3 clinical criteria resulted in a 
2 value of 21.7 with a relatedness 
value of 0.64. Different combinations of the NETest and individual clinical 
criteria exhibited 
2: 15.5‐24.2 and R2: 0.49‐0.69. The combination of the 3 
clinical criteria and the NETest in a logistic regression model provided the 
best fit with a 
2 of 30.31 (p<0.0001), a relatedness value of 0.80, and an AUC 
of 0.96 ± 0.04. The model accuracy was 91.4%. Twenty‐two of 23 (96%) NR 
patients were correctly classified and 10 of 12 (83%) recurrences were 
correctly identified. 
 
FIA (see Section 2) was then undertaken to further examine the importance 
of individual biomarkers and clinical criteria in respect of disease recurrence. 
The NETest (1.8) was 4.5 more important than CgA (0.4) and identified as 
the predominant variable related to recurrence (Figure 6). A combination of 
all 3 clinicopathological characteristics yielded an importance value of 2.3. 
FIA assessment of the value of inclusion of the NETest to the 
clinicopathological characteristics increased the importance numerator to 
4.3. The measurement of tumor transcript levels in blood (NETest) 
significantly improved the utility of grade, tumor size, and LN metastases in 
the accurate prediction of recurrence by almost 2‐fold. 
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Figure 5 - Association between biomarkers, clinical criteria, and disease recurrence. A Accuracy 
of individual factors for the assessment of disease recurrence. CgA accuracy was 66%, tumor 
size >20 mm: 69%, grading: 77%, lymph node (LN) involvement 80%, and NETest 83%. NETest 
and LN positivity were significantly more accurate than both size and CgA (p<0.05). Combining 
the 3 clinicopathological characteristics had the same accuracy as the NETest alone (83%). The 
inclusion of the NETest to the 3 clinical criteria increased the accuracy to 91%. B Logistic 
modeling for strength of association (
2) versus the coefficient of determination (Nagelkerke R2) 
to disease recurrence. CgA levels exhibited almost no relationship (
2=0.02, R2=0.0008) to 
recurrence compared with other clinical criteria. The individual clinical criteria exhibited 
2 and 
R2 values of: grading 7.8/0.28, size 8.7/0.31, and lymph nodes 11.5/0.39. The NETest 
2 value 
was 13 and the R2 0.43 (43%). The combination of all 3 clinical criteria increased the 
2 from an 
average of 9.3 to 21.7 and R2‐value from an average of 33% to 64%. The addition of the NET 
blood transcript information to the 3 clinical criteria increased the 
2 value from 13 to 30 and the 
R2 value from 43% to 80%. The combination of 3 clinical criteria and the NETest exhibited the 
greatest association with disease recurrence. CC, clinicopathological characteristics; CgA, 
chromogranin A; LN, lymph node involvement; NET, neuroendocrine tumors. The coefficient of 
determination is a measure of “relatedness” (Nagelkerke R2). 
 
Figure 6 - Feature performance 
analysis defining the relative 
importance of biomarkers and 
clinicopathological characteristics for 
disease recurrence. CgA was the least 
important feature (0.4) for identifying 
disease recurrence. Individual clinical 
criteria grade (0.8), tumor size (0.92), 
and LN involvement (1.6) were 2‐4 
more important than CgA. The NETest 
(Importance: 1.8) was the single most 
important individual feature (4.5 > 
CgA). The combination of the 3 
clinicopathological characteristics had 
an importance value of 2.3. The 
inclusion of the pNET blood transcriptome increased the importance to 4.3. A combination of 3 
clinicopathological characteristics and the NETest exhibited the greatest importance value.  
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NETest and recurrence/NR 
Six patients (17%) could overall be considered incorrectly classified by the 
NETest (Table 3 and Figure 7). In the NR group (n=23), the NETest incorrectly 
identified 2 patients. Patient 1, 66‐year‐old female, nonfunctional, 6mm G1 
tumor, underwent enucleation. Six years after surgery had an increased 
NETest and CgA—93% and 497 ng/mL— respectively. An MRI 18 weeks 
thereafter identified no recurrent disease. Patient 2, a 67‐year‐old female, 
with a nonfunctional 10mm G1 tumor underwent a central pancreatectomy. 
Biomarkers were measured 8.9 years after surgery and the NETest was 
elevated—73%. CgA was normal. A 68Ga‐DOTATATE‐PET‐CT was 
undertaken 31 weeks later, and no tumor was detected. Both patients were 
designated R1 re sections and neither had post‐operative therapy. 
 
In the recurrence group (n=12), 4 individuals were incorrectly identified by the 
NETest. All 4 patients had nonfunctional tumors and all underwent R0 
resections. Patient 3 was a 47‐year‐old male with a 115mm G2 pNET and 
positive LN (1/6), who underwent leftpancreatectomy. He had completed a 
phosphoinositide 3‐kinase inhibitor clinical study (NPV‐BEZ235) and also 
undergone radiofrequency ablation/embolization for liver metastases. 
NETest and CgA were measured 5.1 years after surgery before initiation of a 
third line therapy, streptozotocin/5‐FU treatment. The NETest was 27% 
(positive) and CgA was 31 ng/mL (normal). Abdominal MRI, 68 weeks after 
biomarker measurement, identified persistent recurrent disease. Patient 4, a 
74‐year‐old male with a 17mm G2 tumor, positive LN (1/3) and perineural 
invasion, underwent a pancreatic corpus resection. Biomarkers were 
measured 8 years after surgery. The NETest was 33% (elevated) and CgA 
was 210 ng/mL (elevated). CT and an Octreoscan, 1 week after biomarker 
evaluation, identified a small LN deposit, which was confirmed at excisional 
biopsy. Patient 5, a 64‐year‐old female, with a 55mm G2, 2/5 LN pNET 
underwent a pancreaticoduodenectomy. Biomarkers were evaluated 1.4 
years after surgery during somatostatin analog therapy. The NETest was 27% 
(elevated) and CgA was 451 ng/mL (elevated). CT identified liver disease, 
which was then treated by streptozotocin/5‐FU. Follow‐up imaging 64 weeks 
later (MRI) was interpreted as stable disease. Patient 6, 71‐year‐old male, 
underwent a left pancreatectomy for a 25mm G1 pNET with perineural 
invasion and LN (0/6). Biomarker evaluation 9.8 years after surgery was 
NETest: 27% (elevated) and CgA: 188 ng/mL (elevated). CT identified local 
recurrence, and he was treated with somatostatin analogs. Follow‐up MRI 68 
weeks later identified stable disease. 
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Figure 7 -  Relationship between NETest and false results for recurrence. Recurrence false 
positive: Two patients (1 and 2) were identified with elevated NETest (scores: 93% and 73%) in 
the absence of image detectable disease. Both had R1 margins and had been followed for 6.3 
and 8.9 years, respectively. In case 1, NETest (93%) and CgA (476 ng/mL) were elevated. The 
time from biomarker measurement to imaging (MRI only) was 18 weeks. In case 2 NETest was 
73% and CgA normal. A 68Ga‐DOTATATE PET/CT was undertaken 31 weeks after biomarker 
measurement was negative. The inability to detect disease despite molecular evidence of a NET 
may reflect the limitations of image sensitivity. Recurrence false negative: Four patients (3‐6) 
were identified with positive NETest scores (>20%) but values that are categorized as low activity 
(ie, <40%) range. All had R0 margins and tumors had recurred 0.3‐2.8 years after surgery (in the 
3 G2 cases) and within 8.5 years in the G1 case. Three of the 4 (3, 5, and 6) had in the interim 
undergone a variety of therapies to treat recurrence. Biomarker evaluation was undertaken 1.2‐
1.3 years after recurrence in these 3 cases. Tumors were all stable at imaging, which is consistent 
with the low NETest activity. The NETest was measured in case (4), 1 week after surgery (lymph 
node excision) for recurrent disease. Presumably, the low value in this instance reflects the 
residual circulating transcript levels from residual low burden disease. Sx, surgery (pancreatic 
resection); Tx, treatment. chromogranin A; MRI, magnetic resonance imaging; NET, 
neuroendocrine tumors.  
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DISCUSSION 
 
To improve the outcomes of patients who have been surgically treated for a 
localized G1/G2 pNET, post‐operative management needs to be optimized 
to detect recurrences at an early stage. Such an identification or effective 
prediction of disease recurrence would facilitate stratification of the patients 
into those at higher risk, who would benefit from adjuvant treatments. Current 
clinical biomarkers in use are limited. In the study, we have demonstrated 
that the NETest effectively detects disease recurrence after curative surgery 
of pNET, and hence can be used to improve quality of the post‐operative 
follow‐up. The NETest has proven to be robust in the discrimination of pNET 
from healthy controls, therefore confirming its utility as a diagnostic for 
pancreatic NET disease25. As it has been already noted in other surgical 
series of the lung and GI tract NETs26,27 higher NETest scores were evident in 
patients with recurrence compared to those without. Furthermore, NETest 
scores >40% were significantly correlated with recurrence, while CgA was 
not. In fact, the utility of CgA was significantly limited by a number of factors. 
First, an elevated CgA was only identified in 10 of 24 (42%) patients with 
residual or recurrent disease. Of these 10, 8 were taking PPIs. Therefore, a 
total of 2 cases (out of 24 patients) or 8% of individuals with elevated CgA 
levels could be unequivocally ascribed to pNET disease. Second, PPIs were 
used in 19 patients (54%). This use elevated CgA in 11 (58%) of them. Third, 
CgA was not related to disease burden in the recurrent group. Indeed, it was 
elevated in only 4 of 9 with distant metastases, and all 4 were receiving PPIs. 
The inconsistent elevation in CgA (presumably due to intermittent use) 
coupled to the high number of patients in whom it is prescribed, as well as 
its unreliable relationship to disease burden results in it being of poor clinical 
value. 
 
Personalization of post‐operative care for pNET is under debate by NET 
experts, but this has not yet led to consensus recommendations on follow‐
up strategies. One explanation is the limited number of monitoring strategies 
available to accurately detect recurrence. Imaging, either anatomical or 
functional, is currently the gold standard for recurrence detection. The blood‐
based tests currently advised by various guidelines (ie CgA) do not 
demonstrate reliable accuracy (sensitivity/specificity metrics) to give support 
to or provide an alternative to imaging. Indeed, the level of evidence for the 
use of CgA is classified by the National Comprehensive Cancer Network as 
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Type 3 “Based upon any level of evidence, there is major NCCN 
disagreement that the intervention is appropriate”40. 
 
In agreement with previously published studies, including one from Genc et 
al10, predictors for recurrence have been identified and include tumor size, 
grade, and LN metastases. In addition, we identified the NETest, but not CgA, 
as the biomarker that could accurately identify recurrence. Receiver operator 
curve analysis, logistic regression modeling, and predictive FIA 
demonstrated that CgA had no value for detecting or predicting recurrence. 
Indeed, the OR for CgA was 1.11 (1.0 is no association). Similarly, the 
2 and 
the Nagelkerke R2 were both lower than 0.1, indicating no relationship to 
disease status (ie, pNET disease recurrence) after surgery. 
 
As a component of the clinical criteria for predicting recurrence CgA was 
identified to have the least importance. Indeed, normal CgA levels were 
identified in the same proportion of patients in each cohort (59% and 61%, 
respectively). Furthermore, while some studies describe a correlation 
between CgA levels and tumor load41-43, our results do not support this 
hypothesis. In contrast, patients with evidence of recurrence on radiological 
imaging, and therefore tumor tissue in situ (R0R group), showed comparable 
CgA levels to patients without evidence of tumor tissue on radiological 
imaging. Indeed, only 4 (of 9) with distant disease exhibited elevated CgA; all 
4 were being treated with PPIs. Elevated CgAs were noted in 5 of 12 with 
known residual (LN positive) disease (R1NR group). Three were taking PPIs. 
Thus, an elevated CgA may be of relevance in <20% of cases. CgA clearly is 
not a useful marker for either pNET disease or for recurrence. In contrast, 
elevated NETest levels were strongly associated with the development of a 
pNET recurrence. The OR and 
2 were 21 and 13, respectively, with a 
relatedness value of 0.43 (43%). Levels were unaffected by PPI use and were 
significantly elevated irrespective of disease burden. The NETest AUC for 
recurrence was significantly better (0.82 vs. 0.51, p<0.05) than CgA. Similarly, 
predictive FIA demonstrated that the molecular biomarker was almost 5‐fold 
more important than CgA (FIA). 
 
We specifically evaluated a cutoff of 40% for the NETest in this surgical 
series. This level has been previously demonstrated to differentiate those with 
“low” risk of disease from those with a moderate or high risk of disease 
activity.34,36 NETest scores >40% have been identified to be prognostic (in 
100% of cases) for disease progression36. Conversely, scores <40% in those 
with stable disease were 100% consistent with image‐confirmation of 
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disease stability.36 In the current surgical study, the NETest was 83% 
accurate for pNET recurrence. 
 
Two individuals (9%) were incorrectly classified in the NR group (n=23). Both 
had undergone R1 resections for small (<20mm) Grade I tumors. Neither 
exhibited LN metastases nor were being treated. The NETest score for 
patient 1 was 93% with an elevated CgA level (497 ng/mL). Patient 2 had a 
NETest level of 73% and CgA of 55 ng/mL. In patient 1 the time between 
biomarker measurement and imaging was 18 weeks. In patient 2 the time 
was 31 weeks. It has previously been noted that NETest scores >70% are 
associated with a median progression‐free survival (PFS) of 0.7 years and 
that up to 25% may not have image demonstrable disease for up to 3 years36. 
Based on previous experience with NETest sensitivity compared with 
imaging, we suspect that both patients will exhibit image detectable disease 
in the future. The image positivity criteria disparity probably reflects the 
difference in sensitivity of detection between imaging tools (CT and MRI) 
compared with transcriptomic analysis. It has been noted that functional 
imaging detects 10% to 30% lesions not identified on an anatomic 
imaging44,45. It is possible that the use of functional (68Ga-DOTATATE PET‐CT) 
would have detected recurrent pNET disease in these patients44. 
 
In a group of patients (n=4) who recurred, the NETest was positive by 
definition (ie, >20%) but was less than the 40% that had been preselected as 
the cutoff point to predict disease recurrence. Blood samples were collected 
1, 64, 68, and 68 weeks after detection of recurrence. Three of these patients 
were being treated with somatostatin analog and streptozotocin/5‐FU 
therapy and were identified as exhibiting stable disease. Thus, the low but 
positive NETest levels likely reflect low activity disease presence (stable). In 
patient 6, the blood sample was collected 1 week after resection of the LN 
with microscopic disease; thus, it was predictable that the NETest score 
would be low (27%). The period of time between biomarker evaluation, the 
effective post‐surgical treatments are consistent with a NETest scores (20%‐
40%) that fall into the low disease activity range. In essence, they confirm the 
presence of disease that is stable as might be predicted after effective 
therapy.  
 
The individual clinical criteria identified by regression analysis exhibited 69% 
to 80% accuracy for predicting recurrence. While a tumor size >20mm was 
strongly associated with recurrence (92% of all recurrences were associated 
with large tumors), only 52% of tumors >20mm recurred. Grading itself was 
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not always indicative of recurrence. While 70% of Grade II tumors did recur, 
only 58% of all recurrences were G2I tumors. While LN status was associated 
with recurrence, the LN ratio did not appear useful as an effective marker 28. 
Only 6 of 12 (50%) R0 that recurred exhibited LNR >0.2. It can thus be 
considered that single clinical criteria alone cannot effectively predict 
recurrence in pNETs. This supports the increasing enthusiasm for generating 
multiplex scoring systems or nomograms to predict disease recurrence10. 
 
Combining the 3 clinical criteria (size, grade, and LN metastases) resulted in 
a model with an overall accuracy of 83%. Recurrence was predicted in 75% 
of cases (9 of 12). The inclusion of the NETest further increased the accuracy 
to 91%. Ninety‐six percent of those who did not recur were accurately 
predicted, whereas 10 of 12 recurrences were identified. This model had the 
highest coefficient of variation (0.8) identifying that it most accurately 
captured information related to disease recurrence. Furthermore, evaluation 
of this model using predictive feature analysis identified it to be >1.8 times 
more important than individual clinical criteria alone for determining 
recurrence. This observation would suggest a role for the measurement of 
blood molecular biomarker in pNET recurrence prediction modeling. More 
accurate stratification of pNET disease using multiple criteria would also 
provide a better basis for defining different clinical treatment groups in the 
evaluation of treatment efficacy. 
 
The NETest+3 clinical criteria model allowed for consideration of a post‐
operative stratification into 3 risk categories to guide followup. Tumors with 
no unfavorable characteristics (eg, <20 mm, low grade, and no LN 
metastasis), with a low NETest score (40%), could be considered less likely 
to recur, and hence less intensive resource dependent post‐operative 
monitoring might be possible. In the presence of a single unfavorable clinical 
criterion, or a NETest score >40%, more aggressive follow‐up protocol with 
yearly consultations and radiological imaging could be advised. Those with 2 
or more unfavorable clinical criteria, and a NETest score >40%, could be 
considered as high risk and the follow‐up frequency intensified. This might 
involve more frequent imaging particularly utilizing more sensitive nuclear 
medicine strategies44 to ascertain disease not identifiable by anatomic 
imaging. 
 
Currently, patients with small pNETs also undergo intensive follow‐up 
because surgical resection is no longer directly indicated according to current 
European Neuroendocrine Tumor Society (ENETS) guidelines4. During the 
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follow‐up of these patients, there is no other possibility to monitor tumor 
progression besides imaging. Under these circumstances, the NETest might 
provide an opportunity to better assess the future malignant potential of the 
disease, particularly as its metrics are significantly better than any other 
biomarker, including pancreatic polypeptide and pancreastatin38. In this 
respect, an elevated NETest (>80%) is strongly associated with disease 
progression34 and “omic analysis” of transcript measurement in the blood has 
been reported to be of value in increasing the accuracy of the prediction of 
tumor progression26,33. Thus, the gene cluster (omic analysis) of NET 
transcript expression in individuals with small pNETs (<20 mm) might be 
useful to identify those with a high risk of disease progression. Such patients 
might benefit from pre‐emptive surgical resection despite small tumor size. 
Moreover, elevated levels after surgery are effective prognostic markers and 
can be used to identify those who would benefit from early intervention 
because of risk of recurrence26,27. Ultimately, we envisage that the NETest 
could be evaluated at least annually after surgery and included in the 
algorithm to provide an updatable real-time patient risk status. The frequency 
of testing would depend on the risk of progression. Cost‐effectiveness would 
be determined through changes (decreases) in imaging as has been recently 
noted46. 
 
The current study confirms that CgA has no role in predicting pNET disease 
recurrence. It has little accuracy, was the poorest feature for prediction and 
the OR (1.1) was no different to using no biomarker at all. If the patient is 
receiving PPIs, the value of CgA is even further obfuscated. It seems likely 
that use of a molecular blood test as an accurate marker of disease 
recurrence or progression might be of clinical utility. 
 
The study has some limitations. As with many investigations in the NET field 
sample sizes for each group are small and patients identified retrospectively. 
Patients were older than controls but this has not been identified to be 
relevant to the NETest; no correlation has been noted between age and 
transcript levels29. The follow‐up duration of patients in the R0NR group is 
shorter compared to the other patient groups (31 months vs. 105 and 92.5 
months, respectively). As recurrence is typically seen within the first 5 years 
after surgery, a follow up of 31 months may not be adequate to identify all of 
those who will recur. 
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CONCLUSION 
 
Identification of, or prediction of pNET recurrence at an early time point is a 
critical medical necessity to facilitate further treatment and improve survival. 
Current clinically used criteria are effective, but inclusion of a blood biomarker 
that will improve accuracy would be of added value. In this respect the 
NETest has performance metrics that conform to NIH standards and detects 
and predicts recurrence after curative resection of G1/G2 pNET. Our study 
indicates that blood transcript analysis of pNETs added biomolecular value 
to support the current clinical and radiological parameters used in post‐
operative follow‐up. Larger prospective studies are warranted to more fully 
explore the utility of the NETest in the identification of postoperative residual 
pancreatic NET disease or recurrence and to help better stratify patients for 
post‐surgical treatment. 
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ABSTRACT 
 
Rationale. pancreatic neuroendocrine tumors (pNET) are more often 
diagnosed incidentally due to the use of better imaging techniques. Surgical 
resection is the only curative treatment and long term follow-up indicates a 
survival benefit for patients who underwent primary resection. However, 
pancreatic resections are associated with serious postoperative morbidity. In 
addition, recent literature shows that incidentally found pNET have a 
significant smaller size and are more commonly associated with lower tumor 
stages. Progression or tumor growth in small incidentally found non-
functioning pNET seems minimal. Therefore, the European Neuroendocrine 
Tumor Society (ENETS) has updated their guidelines; surveillance is now 
recommended for patients with non-functional pNET <2cm. Although this 
approach seems safe, long term follow-up data are needed to guarantee the 
safety of this policy. 
 
Objective. To monitor long term effects of a non-operative management of 
small pNETs. 
 
Study design.  A prospective, multicentre, cohort in collaboration with all 
Dutch Pancreatic Cancer Group (DPCG) affiliated centers that treat patients 
with pNET. 
 
Study population. patients diagnosed with a pNET <2cm. 
 
Endpoints. Tumor progression and survival will be the primary outcomes. In 
addition, patients who do undergo a resection despite the guideline will be 
observed. The reasons to deviate from the initial therapy will be investigated. 
A secondary outcome will be the quality of life of all patients that are 
diagnosed with a pNET <2cm, regardless of received therapy. 
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INTRODUCTION 
 
Neuroendocrine tumors of the pancreas (pNET) comprise 1-2% of all 
pancreatic malignancies and have an incidence of 1-2/million/year1. 
Improved diagnostics and pathological recognition have led to an increased 
detection of pNET. pNETs are mostly identified on abdominal imaging 
performed for other indications2. Since pNET are relatively rare, large 
prospective studies, let alone randomized controlled trials, on diagnostics 
and treatment are very difficult to perform. 
 
PNET are divided in functioning and non-functioning tumors. Functioning 
tumors are defined as tumors with hormonal overproduction causing a 
clinical syndrome.  Functioning pNET, regardless of size, form an indication 
for resection. Other pNET are diagnosed during surveillance programs for 
patients with genetic syndromes such as MEN1 or Von Hippel Lindau 
disease. The latter genetically based pNET are not the focus of this protocol, 
since specific guidelines for these patients are available. Non-functioning 
pNET are often diagnosed because of pain of abdominal complaints but also 
incidentally during abdominal imaging for other indications. Larger non-
functioning pNET (>2cm) form an indication for resection but consensus is 
lacking on the treatment of small non-functioning pNETs. 
 
Patients with pNET have a much better prognosis then patients with 
pancreatic adenocarcinoma, with 10-year survival rates after resection 
exceeding 80%.  Especially patients with small pNET seem to have an 
excellent prognosis and the latest guidelines suggest a wait-and-see protocol 
for patients with non-functioning pNET <2cm1,2. Most of these patients in 
surveillance protocols do not show tumor progression. However, some 
studies report that eventually resection during follow-up was performed in 
14-25% patients3-5. Because these series are retrospective, indications for a 
wait- and-see strategy and late surgery are difficult to assess.  
 
Therefore, in this nationwide prospective PANDORA cohort, all patients with 
small non-functioning pNETs (<2cm) will be registered and prospectively 
followed. Indications for initial and later treatment strategies and policy 
changes will be recorded. 
 
Objectives 
The aim of this prospective cohort is to analyze the long-term effects of the 
non-operative management of pNET <2cm. Tumor progression will be 
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monitored and the amount of patients that will undergo a resection regardless 
of the indication will be assessed. In addition, the reasons to undergo a 
resection will be analyzed. Patients that will receive a non-operative 
treatment after initial diagnosis will be compared to the patients that undergo 
a resection despite indication for surveillance. Furthermore, a comparison 
with a large retrospective database of a similar patient population will also be 
made. 
 
 
STUDY DESIGN 
 
All patients that are diagnosed with a NF-pNET <2cm at the participating 
centers will be registered in the PANDORA database. Data collection will be 
performed in an anonymous database, not linked to private details of patients 
used for sending Quality of Life (QoL) questionnaire or requiring hospital data. 
Every hospital including patients will need a local study-representative. 
Registration will be performed by either the clinician or the PANDORA-
representative through the study website (www.amc.nl/pandora). The study 
coordinator (SC) will collect data on treatment and diagnostics and will 
directly contact patients by mail/email for QoL assessments. The time of 
follow-up will be least 10 years, or till date of death.  
 
 
STUDY POPULATION  
 
Inclusion criteria  
-  Patients > 18 years 
- Able to read and write Dutch/English and fill in QoL-questionnaires 
- Radiology (or pathology) proven NF-pNET <2cm 
- Imaging with CT/MRI showing no metastases or suspected lymph  
nodes. 
 
Exclusion criteria  
- Patients with MEN1 or another genetic predisposition for pNET 
- Functioning pNET (gastrinoma, insulinoma, etc) 
- pNET grade 3 
 
 
08 08 
PANDORA 
	 143 
DIAGNOSIS 
 
The flowchart is presented in Figure 1. All patients are diagnosed as stated 
below. Patients with a pNET diagnosed after resection will be followed as 
stated in the PANDORA postoperative follow-up protocol. 
 
Hormones  
• Chromogranin A   Only initially 
• Only peptic ulcers/abdominal pain  Gastrin 
/ diarrhoea  
• Only in hypoglycemia   Insulin and C-peptide 
• Complaints unclear    Endocrine evaluation 
 
 
 
 
Figure 1 – PANDORA flowchart. 
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METHODS 
 
Imaging 
The diagnosis of pNET must be made with high suspicion on at least 2 
radiological techniques, preferably by combining anatomical and nuclear 
imaging. Pathology through FNA is not directly recommended since the risk 
of pancreatitis and sampling error. Only in case of doubt cytology/histology 
is indicated. 
• Contrast enhanced CT scan or MRI 
• 68Ga-DOTATATE PET-CT   
• 18FDG-PET in NEC / Grade 3 pNET 
 
68Ga-DOTATATE PET-CT is advised as preoperative assessment of 
dissemination in all G1/G2 pNET. 
 
 
Genetics   
Optional: PTH /calcium, only at initial visit (MEN 1 screening) 
 
 
Pathology  
Endosonography (EUS) with Fine Needle Aspiration (FNA) or Fine Needle 
Biopsy (FNB) with Ki67 index (or grading) is only advised when there is doubt 
of diagnosis pNET through imaging, and not for those who will undergo 
resection. 
 
  
08 08 
PANDORA 
	 145 
FOLLOW-UP 
  
Wait-and-see protocol for patients with non-resected pNET 
Outpatient visits combined with imaging as in the following schedule (MRI 
favors CT scans to reduce radiation-dose): 
 
Year 1  3 months EUS 
  6 months  MRI/CT 
  9 months Outpatient /telephone consultation  
  12 months  EUS 
Year 2  18 months MRI /CT 
  24 months MRI/CT 
Year 3  30 months Outpatient visit / telephone consultation 
  36 months MRI/ CT 
Year 3-10 MRI/ CT every 12 months 
 
If during follow-up the tumor size exceeds the >2cm, or if tumor growth 
>0.5cm/year is visualized, resection should be advised. All other tumor 
characteristics, such as suspected lymph nodes or suspected metastases 
should be proven with cytology and/or be considered in the treatment 
strategy. Preoperative imaging though 68Ga-DOTATATE PET-CT to assess 
dissemination of disease is advised. 
 
 
Follow-up protocol after resection 
6 months postoperative  MRI/CT  
Thereafter every 12 months  MRI/CT or 68Ga-DOTATATE PET-CT  
 
Follow-up at least until 10 years postoperatively. 
 
 
ADVISORY BOARD 
 
Two NET specialists from each of the 4 Dutch ENETS-centers are asked to 
be part of the PANDORA Advisory Board. This advisory board can be 
counselled for medical expertise, management and/or other questions 
associated with PANDORA.  
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GENERAL CONCLUSION AND FUTURE PERSPECTIVES 
 
As shown by multiple population based studies, the incidence of pancreatic 
neuroendocrine tumors (pNET) is rising and is expected to rise further due to 
increasing knowledge and the use of advanced radiological and nuclear 
imaging techniques1,2. Patients with pNET generally have a favorable 
prognosis but despite efforts the overall survival is not improving over time3-
5. Typically, patients experience long delays before a diagnosis (5–7 years), 
and most lack access to the multidisciplinary care necessary for optimal 
management of these complex tumors. Furthermore, the majority of patients 
are still diagnosed with metastatic disease. Disappointingly, the increase in 
the number of patients diagnosed with pNET seems to have surpassed our 
knowledge of this disease. In view of the slow progress made for this 
condition, reliable and well executed studies are ungently warranted. 
 
Survival primarily depends on the tumor grade and tumor-node-metastasis 
(TNM) stage, showing superior outcomes after surgical resection for almost 
all patients (Chapter 2). Surgical resection is considered the only curative 
treatment option and represents the treatment of choice for any localized 
pancreatic neoplasm6-8. A more aggressive treatment approach has 
increasingly been described in the literature for selected patients with distant 
metastases, as multiple studies show survival benefit after either resection of 
(solitary) liver metastases and/or after resection of the primary tumor in the 
presence of distant metastases9-12. On the contrary, small pNET seem to have 
a more indolent behavior and the need for surgical resection of these tumors 
is under debate. 
 
Recurrence 
The growing incidence of pNET has led to an increase of patients diagnosed 
with localized, and thus resectable disease. Between 2008 and 2013 the 
number of patients who underwent a pancreatic resection for pNET has 
shown a 1.6-fold increase within the Netherlands (Chapter 2). To improve the 
outcome of patient who have been surgically treated, postoperative 
management needs to be optimized. Multiple studies have shown significant 
decrease of survival in patients with recurrence after curative treatment of 
pNET, suggesting that postoperative follow-up should be designed to detect 
recurrence (Chapter 3 and 4). However, clear guidelines for postoperative 
follow-up have not yet been described13, 14. Lack of data regarding recurrence 
rates and median time to recurrence presents a major obstacle to designing 
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studies of appropriate power and duration to overcome this nescience. A 
meta-analysis of published literature on patients with well-differentiated 
pNET who underwent a curative resection shows that recurrence is seen in 
9-18% within 5 years after surgery (Chapter 3). This indicates that recurrence 
of well-differentiated pNET is not uncommon and should not remain 
untreated. Several predictors for recurrence have been presented in the 
literature, making it possible to identify high risk patients3,13. In a large 
database of patient with non-functioning pNET (NF-pNET) predictive factors 
for the development of recurrent disease were analyzed. Tumor grade, the 
presence of lymph node metastases and perineural invasion were 
independently associated with recurrence within 5 years after surgery, 
leading to the development of a scoring system to estimate the risk of 
recurrence and identify high-risk patients (Chapter 4, Figure 1). The 
predictors presented in this scoring system correspond to the literature and, 
when combined, showed to be a better predictor of recurrence than the 
grading classification of the World Health Organization (WHO). The clinical 
relevance of tumor grade to determine the postoperative treatment strategy 
of pNET has been under debate because of the wide range of the Ki67 
proliferation index, in particular for grade 2 and 3 tumors15-17. Heterogeneity 
of pNET is increasingly described leading to a recent update of the WHO 
grading system, subdividing high-grade tumors into well-differentiated G3 
neuroendocrine tumors (NET) with lower Ki67 and a better prognosis and 
poorly differentiated G3 neuroendocrine carcinoma (NEC) with higher Ki67 
values and unfavorable prognosis18. Although clear upper or lower limits to 
differentiate between these high-grade tumors are not provided, differences 
in disease behavior and response to treatment are suggested19-21. Some NET 
experts promote a similar development for G2 tumors, for which the Ki67 
ranges from 3-20%. Already a cutoff of 10% has being advised to select 
patients suitable for liver transplantation or inclusion in the Clarinet study, 
supporting heterogeneity for well-differentiated pNET aswell22,23.  
Furthermore, several studies describe a higher discriminative capacity when 
G1 and G2 pNET are divided by a Ki67 cutoff of 5% instead of 3%24-26. The 
same is seen when the proliferation index is analyzed for the prediction of 
recurrence after curative resection of pNET (Chapter 5). In a large 
retrospective study of 241 patients with well-differentiated pNET, patients 
with G1 pNET (Ki67 0-2%) showed a similar risk of recurrence within 5 years 
after surgery compared to pNET with Ki67 of 3-5%. Moreover, pNET with a 
Ki67 of 6-20% had a threefold higher risk to develop recurrence and showed 
significantly shorter survival than tumors with Ki67 <5%. These results 
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contribute to strengthen the Recurrence Score by updating the criteria for G2 
tumors to pNET with Ki67 6-20%. Discrimination of high-risk and low-risk 
patients will be more accurate, providing the possibility to customize 
postoperative treatment of patients based on the risk to develop recurrence. 
High-risk patients might benefit from intensified postoperative monitoring or 
adjuvant treatment while unnecessary follow-up or treatment for low-risk 
patient, especially for pNET with a Ki67 of 3-5%, may be limited. 
 
Biomarkers 
The introduction of personalized postoperative treatment strategies is under 
debate by NET experts, resulting in the lack of uniform follow-up 
recommendations. A possible explanation is the limited number of monitoring 
strategies available to detect recurrence accurately. Radiological imaging 
with Computed Tomography (CT) or Magnetic Resonance Imaging (MRI), and 
nuclear imaging with 68GA-DOTATATE PET-CT is currently the gold standard 
to detect recurrence6. A fundamental issue in the management of 
gastrointestinal NEN is the absence of reliable biomarkers that can provide a 
measure of the underlying mechanism of tumor development and growth. 
Chromogranin A (CgA) used to be considered as the most useful biomarker 
for the detection of metastases after curative resection of pNET27. However, 
CgA does not achieve the desired metrics for biomarker sensitivity and 
specificity. The sensitivity of CgA varies from 24-88% in the literature, 
showing increased accuracy in patients with high tumor load6, 28, 29. However, 
measurements show low specificity as CgA is also elevated in other neoplasia 
(pancreatic, prostate, small cell lung neoplasia) as well as in a variety of 
cardiac and inflammatory diseases, renal failure and the use of acid 
suppression medication, making it ineffective as first-line diagnostic for 
pNET30-35.  
 
The term liquid biopsy has been used to describe the capability of detecting 
tumor cells in blood and has been effectively used in other cancers36,37. 
Expanding knowledge in the genomic landscape of pNET and the relatively 
limited complexity of the mutational signatures that characterize their 
pathogenesis make these tumors ideally suited for this technique38. Recently 
a multianalyte blood-test based on circulating RNA, the NETest, has been 
described by Modlin et al. showing a sensitivity and specificity >93% for the 
diagnosis of NET39. As a biomarker, the NETest also confirmed to be effective 
in the detection of pNET recurrence during postoperative follow-up (Chapter 
6). In a prospective study among 35 patients, the NETest showed an 83% 
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accuracy in detecting recurrence after curative resection of well-
differentiated pNET, compared to 59% for CgA. NETest scores were 
significantly higher in patients with recurrence compared to patients without 
recurrence or with R1 resections, and showed the strongest association to 
recurrence with an odds ratio (OR) of 21 (vs. 1.11 for CgA). Other 
clinicopathological characteristics associated with recurrence included 
tumor grade (OR 9.3), lymph node metastasis (OR 14.3) and tumor size (OR 
14.3). Combining the NETest with clinicopathological characteristics showed 
to be ~2x effective in detecting recurrence, reaching an accuracy of 91%. 
These results suggest that there is no role for CgA in predicting disease 
recurrence and that the NETest can improve the quality of postoperative 
follow-up. Together with clinicopathological criteria, the NETest is useful in 
accurately identifying high-risk patients and aid postoperative treatment 
strategies. Corresponding clinicopathological characteristics with the 
Recurrence Score confirm the prognostic accuracy of these variables and 
their clinical relevance in predicting recurrence. Furthermore, the results 
suggest a broader applicability of the NETest in the treatment of pNET. The 
NETest has proven to be robust in the discrimination of pNET from healthy 
controls, confirming its utility as diagnostic for pNET disease. Furthermore, 
other studies have shown strong association of NETest scores and tumor 
progression, providing the possibility to monitor treatment effect40-42. The 
NETest might be useful in patients with small pNET, discriminating between 
those with a high risk of disease progression who might benefit from pre-
emptive surgical resection and tumors with less malignant behavior for whom 
the risks of an operation do not outweigh the risk of disease progression. 
Moreover, the NETest might also be useful in the follow-up of small pNET 
who undergo a conservative approach to assess tumor growth or changes in 
behavior. Ultimately, we envisage that the NETest is used regularly in all 
stages of disease to provide an updatable real-time patient risk status. 
 
Small pNET 
The improvement of cross-sectional imaging techniques significantly 
increases the detection of small and often asymptomatic pNET. It remains 
questionable if all these lesions should be routinely resected. Until recently, 
surgical resection was the gold standard for all localized pNET lesions. The 
latest update of the European Neuroendocrine Tumor Society (ENETS) 
guidelines for the management of well-differentiated non-functional pNET 
(NF-pNET) advocate the possibility of a conservative approach, rather than 
surgical resection, for small tumor <2cm6. The objective is that these small 
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lesions are likely benign or intermediate risk and will show limited to no 
growth or metastasis. Moreover, the guidelines state that only 6% of NF-
pNET <2cm would be malignant when incidentally discovered43. Data 
supporting surveillance, however, are controversial as it is based on a small 
number of retrospective cohort studies44,45. Correspondingly, a nationwide 
population based study in the Netherlands shows survival benefit for patients 
who underwent surgical resection for T1N0 pNET (Chapter 2).  
 
For many clinicians, it remains unclear whether it is safe to adopt this rigorous 
change of treatment at the moment, as the same 2016 ENETS guidelines 
clearly state that additional data are needed to guarantee the safety of this 
policy. Besides the lack of reliable prospective data on small pNET, a number 
of important variables remain underexposed when opting for conservative 
approach. For example, it is well demonstrated that tumor grade and lymph 
node metastases could play a role in the prognosis of many pNET. Both 
variables are known to have a strong correlation with pNET recurrence after 
curative resection (Chapter 4), suggesting increased malignant behavior for 
G2 pNET and those with lymph node metastases. At the moment, it is not 
possible to determine the grade of a pNEN other than through pathological 
assessment. However, fine-needle aspiration (FNA), which is undesirable in 
small lesions because of the high risk of post-FNA pancreatitis, is not 
accurate in differentiating the grade of pNEN and frequently shows sampling 
error46,47. Other methods to estimate the malignant potential of pNET have 
not yet been described. As described above, the NETest might be able to 
offer a solution in estimating the behavior of pNET in order to determine the 
need for surgery. 
 
The PANDORA study is a nationwide prospective cohort in which all patients 
with NF-pNET <2cm diagnosed in the Netherlands are registered and 
prospectively followed (Chapter 8). Indications for initial and later (changed) 
treatment strategies, tumor progression, quality of life and survival will be 
assessed. With this prospectively maintained database, in collaboration with 
the international ASPEN study of professor Falconi (ClinicalTrials.gov 
Identifier NCT03084770), we hope to answer the question if active 
surveillance in small, sporadic pNET may be a good alternative to surgical 
management and whether it is necessary to expose this select patient 
population to a high surgical risk. In contrast to the guidelines advising a 
conservative approach for small pNET, the PANDORA protocol presents a 
clear follow-up regimen for both patients who receive surveillance as well as 
patients who undergo a pancreatic resection. To prevent post-FNA 
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complications, diagnosis must be based on 2 imaging modalities, ideally a 
combination of anatomical imaging (i.e. CT or MRI) and nuclear imaging 
(preferably 68GA-DOTATATE PET-CT), especially since the latter shows very 
high sensitivity in the detection of pNET in different studies48,49. Database 
analysis of patients who underwent surgical resection of a pancreatic mass 
in the Academic Medical Center Amsterdam showed that this method is safe 
as no adenocarcinoma was missed when the radiologist suspected pNET on 
imaging. Therefore, tumor tissue analysis for the diagnosis of pNET is only 
advised in those patients where there is doubt about the diagnosis on 
imaging. In addition to imaging, the NETest may have a role in the diagnosis 
of pNET and estimating the malignant potential of small tumors in the future. 
 
Future perspectives 
For some time, lack of knowledge has resulted in the delayed development 
of better treatment strategies for patients with localized pNET disease. 
Increasingly, it becomes clear how to assess the behavior of pNET and 
initiate therapy accordingly. To improve the postoperative outcomes of 
patients with well-differentiated pNET, a number of issues will have to be 
prioritized.  
 
Firstly, there is a strong need for clear and uniform follow-up regimes, 
assuming survival benefit for the early detection and treatment of tumor 
recurrence. In Table 1 we propose such a protocol based on the expected 
risk profile of the patient, which can be determined by the updated 
Recurrence Score (Chapter 4 and 5) and the NETest (Chapter 6). Patients 
with a Recurrence Score of 24 or higher (meaning that one of the following  
 
Table 1 - Proposed follow-up protocol after curative resection of well-differentiated pNET. 
 Yearly follow-up Half-yearly follow-up Minimum duration 
 
Low-risk patients 
 Ki67 0-5% 
 No lymph node 
metastases 
 No perineural invasion 
 NETest <40% 
 
Clinical assessment 
NETest 
Imaging, alternating 
 CT/MRI 
 Nuclear imaging  
 
	
NETest scores = follow-
up as high-risk patients, 
until 3x stable NETest <40% 
 
 
 
>5 years 
 
High risk patients 
 Ki67 >6% 
 Lymph node 
metastases 
 Perineural invasion 
 NETest >40% 
 
Clinical assessment 
NETest  
Imaging, alternating 
 CT/MRI 
 Nuclear imaging  
 
Clinical assessment 
NETest 
 
(additional imaging) 
 
10 years 
0909 
09.  
	156 
tumor characteristics must be present: pNET with Ki67> 6%, lymph node 
metastasis or perineural invasion) or with a NETest score> 40% will be 
considered as high-risk, while those with a Recurrence Score below 24 and 
a NETest <40% will be considered low-risk patients. For all patients, yearly 
consultations with clinical assessments, laboratory tests (NETest) and 
imaging is advised for the first 5 years. Ideally, imaging is alternated between 
radiologic and somatostatin receptor imaging to achieve the highest 
accuracy. Half-yearly hospital visits with laboratory tests are advised for high-
risk patients and low-risk patients with increasing NETest scores. Based on 
the clinical findings and laboratory results, additional imaging may be 
obtained. For low-risk patients a minimum follow-up duration of 5 years is 
advised, while a follow-up of at least 10 years is encouraged for high-risk 
patients as late recurrences have been described14. Based on the median 
time to recurrence, the interval between hospital-visits can be increased if 
there are no signs of pNET recurrence after 5 years. By implementing this 
protocol, patients will be monitored in a more structured way, resulting in 
early detection and treatment of recurrence. Conceivably, this will lead to 
improved survival of curatively treated patient and at the same time provide 
the data necessary to demonstrate the beneficial effect of early detection of 
recurrence.  
 
The restricted availability and limited data due to the rare nature of this 
disease is another reason for the slow development of optimal treatment 
strategies. Proper international agreements on disease stage, grade and 
treatment, patient selection and study design should therefore be another 
priority to obtain fast and reliable data from well-executed studies. During the 
writing of this thesis it became apparent that many studies use different 
definitions, for example to define the appropriate patient selection. 
Heterogeneity is a known problem for NEN in general, making a strict patient 
selection all the more important to be able to draw useful conclusions from 
studies. The same was seen for the definition of recurrence, resulting in data 
not being comparable and availability of already limited data being even 
further restricted. Initiation of prospective studies on pNET disease is 
challenging, given the low patient numbers and scattered presentation in 
different centers. However, well-designed and executed prospective studies 
will ultimately result in the availability of more reliable data in the shorter term. 
Although such studies are often time consuming, less reliable studies, often 
carried out retrospectively with poorly comparable data, lead to unreliable 
outcomes, discussion and noise. Therefore, we want to advocate for clear 
09 09 
General conclusion and future perspectives 
	 157 
agreements, not only to optimize the treatment of patient with pNET but also 
to optimize scientific research and obtain useful results. 
 
Lastly, with the current knowledge and results presented in this thesis, it is 
no longer possible to deny that recurrence occurs regularly and that patients 
with a high-risk can be identified. In addition to intensified follow-up, these 
patients might also benefit from adjuvant treatment. Several systemic and 
local ablative treatment options are known for NEN, however data on the 
effect of these treatments only exists for patient with disseminated disease. 
The use of these treatments on patients without detectable tumor load is 
unknown, making it difficult to set up studies to investigate the role of 
adjuvant therapy. To overcome some of these obstacles, a collaboration with 
a large group of international experts in pNET treatment has been initiated. 
This consensus study resulted in 11 comprehensive recommendations to 
encourage clinical research on adjuvant therapy and facilitate the 
development and coordination of relevant clinical trials with support from 
experts in the field (Chapter 7). A randomized controlled trial investigating 
the recurrence preventive effect of chemotherapy with a regimen of 
capecitabine and temozolomide is advised. When the availability or Peptide 
Receptor Radionuclide Therapy (PRRT) improves, the advice is to reconsider 
this technique as adjuvant treatment. With these recommendations, it will be 
possible to initiate a study on the short term and it is expected that the first 
results on the effects of adjuvant therapy can become evident in a few years.  
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SUMMARY 
 
Pancreatic neuroendocrine tumors (pNET) are rare neoplasms with an 
increasing incidence due to the widespread use of cross-sectional 
radiological imaging and expanding knowledge. Reliable and well executed 
studies with an adequate patient selection are scarce, mostly because to the 
limited availability of data. As a result, the survival of patients diagnosed with 
pNET does not seem to increase. To improve the postoperative outcome of 
pNET it is important to understand the survival of patient who have 
undergone a surgical resection and identify those patients who have a high 
risk to develop recurrence. Clear and uniform follow-up recommendations 
are warranted in order to detect and treat recurrence early. This thesis 
provides insight into the pre- and postoperative management of patients with 
well-differentiated pNET (low-grade G1 and moderate-grade G2 tumors) 
without distant metastases or hereditary syndromes.  
 
Because studies on rare diseases often contain small patient numbers, we 
have performed a large population-based study on the treatment and related 
survival of pNET. In Chapter 2, patients diagnosed with pNET in the 
Netherlands between 2008 and 2013 were identified from the Netherlands 
Cancer Registry database. The overall survival did not change during this 
period. Metastatic disease was seen in approximately half of the patients. 
Higher Tumor-Node-Metastasis (TNM) stage and tumor grade were 
significantly associated with worse survival. The majority of patients received 
surgical treatment and the number of patients who underwent a pancreatic 
resection increased significantly in time. Surgical resection showed favorable 
outcome in almost all subpopulations. For patients with the most indolent 
tumors (T1M0, meaning pNET <2cm without distant metastases) a significant 
survival benefit was seen after surgical resection compared to patients who 
did not receive treatment. In addition, patients with distant metastases 
showed significant better survival after resection of the primary tumor. At the 
moment, international guidelines advise surgical resection for localized pNET 
>2cm of size. These results suggest that patients with small tumors and those 
with distant metastases might also benefit from surgical resection, despite 
current recommendations. 
 
Recurrence after curative resection of well-differentiated pNET has been 
assumed to be uncommon, because of the indolent nature of neuroendocrine 
tumors in general. Different recurrence rates have been reported, whereby 
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the importance of disease relapse remains unclear and is not always 
recognized. Chapter 3 presents the results of a systematic review and meta-
analysis of the existing literature to provide reliable recurrence rates for this 
patient population. Strict inclusion criteria were used to minimize 
heterogeneity, a known and common problem in pNET research. Eight 
studies, comprising 734 patients, met the inclusion criteria. Recurrence after 
curative resection of G1 or 2 pNET was seen in 9-18% after a mean time of 
39.4 months. Subgroup analyses showed significant lower recurrence rates 
for patients with G1 tumors (8%) and R0-resentions (10%). Distant 
metastases, predominantly in the liver, were seen more often than local 
recurrence and regional lymph nodes metastases. Survival after recurrence 
was poor, with a mean of 38.9 months. Factors reported to be associated 
with recurrence include tumor size, grade, lymph node metastases, 
perineural invasion and R1 resection. From these results, we conclude that 
recurrence after curative resection of well-differentiated pNET is not rare and 
has serious consequences for the survival. 
 
Identification of patients who have a high risk of recurrence may aid 
postoperative treatment and the development of both follow-up regimens 
and studies on adjuvant therapy. In Chapter 4 we describe the development 
of an easy tool to estimate the risk of recurrence in patients who underwent 
a curative resection of well-differentiated non-functioning pNET (NF-pNET). 
In a large cohort of 211 patients, recurrence was seen in 17% after a median 
time of 43 months. Patients who developed recurrence showed significant 
lower survival rates compared to patients without recurrence. Recurrence-
free survival curves showed that recurrence was predominantly seen in the 
first 5 years after resection. Predictors for recurrence were G2, lymph node 
metastasis and perineural invasion, corresponding with the literature. The 
recurrence-score was developed on the basis of these predictors. In this 
scoring system, patients are awarded points based on the presence or 
absence of each of the predictive factors. The total points correspond to the 
probability to develop recurrent disease within 5 years after surgery. Internal 
validation showed good discriminative ability of the recurrence-score that 
was higher compared to the grading classification of the World Health 
Organization (WHO). A cut-off of 24 points was determined as the appropriate 
score to classify patients as high or low risk of recurrence, with a sensitivity 
of 91% and specificity of 62%. Patients who were considered low-risk 
(recurrence-score <24) showed a significantly better ten-year disease 
specific survival compared to patients who had a high-risk in developing 
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recurrence (recurrence-score >24). In the future, the recurrence-score can be 
used to customize follow-up regimens on the basis of the risk profile of 
patients who underwent a curative resection of G1 or G2 NF-pNET.  
 
Prognosis of pNET is highly dependent on tumor grade, which is determined 
by the Ki67 proliferation index. Despite this knowledge, postoperative follow-
up is the same for G1 and G2 tumors and adjuvant therapy is currently not 
indicated. There has been debate about the wide range of Ki67 within the 
different grades, resulting in a recent update of the grading system for high-
grade tumors. In Chapter 5 we hypothesized that pNET with a Ki67 <20% 
(low and moderate grade pNET) are a heterogeneous group of tumors with 
different postoperative disease course as well, and investigated the role of 
Ki67 in predicting recurrence and survival after curative resection. In a large 
cohort was seen that tumors with Ki67 6-20% recurred significantly more 
often compared to tumors with Ki67 0-5%. Furthermore, tumors with Ki67 6-
20% significantly more often showed unfavorable tumor characteristics 
compared to tumors with Ki67 0-5%. The Ki67 cut-off of 5% also showed 
adequate discriminative abilities with the highest sensitivity and specificity for 
predicting recurrence. Although the discriminative ability of this proposed 
Ki67 cut-off was comparable to that of the WHO grading classification, an 
additive value was seen as 10% of patients were correctly re-classified based 
on their risk of recurrence with this new method. In addition to Ki67 >5%, 
tumor larger than 4 cm and lymph node metastases were independently 
associated with recurrence. These results can be used to strengthen the 
recurrence-score presented in Chapter 4; by updating the criteria of ‘G2 
tumors’ to ‘tumors with Ki67>5%’ it will be possible to identify high-risk 
patients more accurately. Moreover, patients with Ki67 3–5% (approximately 
15% of our cohort) will be downgraded by this modification, limiting 
unnecessary treatment or monitoring for these patients. 
 
Current guidelines recommend Chromogranin A (CgA) as the biomarker to 
evaluate tumor recurrence during follow‐up. However, the clinical utility of 
CgA is questionable, given its moderate accuracy and regular false-positive 
values. Recently the NETest was presented, a liquid biopsy strategy showing 
a sensitivity and specificity of >93% for the detection of neuroendocrine 
tumors in the gastrointestinal tract. In Chapter 6 we investigated the 
prognostic accuracy of the NETest, compared to CgA and other known 
clinical criteria associated with pNET recurrence, to determine its usefulness 
during postoperative follow-up after curative resection of pNET. In this 
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prospective surgical cohort study, the NETest was significantly higher in 
patients with recurrence compared to patients without recurrence or R1 
resections. CgA did not show different values between these groups and 
showed no positive correlation to recurrence in several analyses. The NETest 
was an independent predictor for recurrence, together with grade, lymph 
node metastases and tumor size. Combining these three clinicopathological 
characteristics with the NETest showed an accuracy of 91% in predicting 
recurrence, and was almost 2x more effective than clinicopathological 
characteristics alone. In conclusion, the NETest outperforms CgA as a 
biomarker to guide postoperative follow-up and facilitates the effective 
identification of high-risk patients, especially when combined with the 
recurrence-score. 
 
Accurate identification of high-risk patients provides the possibility to 
customize postoperative treatment.  Adjuvant therapy is currently not 
indicated but might be beneficial to prevent recurrence after curative 
treatment. Lack of data regarding this disease, in particular following curative 
resection, presents a major obstacle to designing studies on the role of 
adjuvant therapy in high-risk patient. Chapter 7 presents the results of a 
consensus study, a collaboration between multiple international experts in 
the treatment of pNET. The aim was to overcome some of these obstacles 
and provide recommendations to encourage clinical research on adjuvant 
therapy in pNET. All participating experts considered the risk of recurrence 
after curative resection of concern and agreed that there is a need for 
research on this topic. A randomized-controlled trial, both arms including 
high-risk patients identified with the modified version of the recurrence-score, 
is advised as the optimal study design. The board availability and general 
good tolerability have led to the decision to advise chemotherapy with a 
regimen of capecitabin and temozolomide (CapTem) to serve as adjuvant 
therapy. However, the study group notes that Peptide Receptor Radionuclide 
Therapy (PRRT) shows promising results and will have to be reconsidered 
when availability has increased. Power calculations based on the reported 
response rates of CapTem in patients with advanced disease show that a 
multicenter approach seems inevitable to acquire the number of patients 
necessary to achieve decent and reliable results. 
 
For long, surgical resection was the gold standard for pNET without distant 
metastases. Nevertheless, recent studies report little to no progression of 
small pNET, suggesting excellent prognosis and low morbidity when 
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refrained from surgery. Based on these results the European Neuroendocrine 
Tumors Society (ENETS) recently updated their guidelines, recommending a 
wait-and-see approach for small non-functioning tumors. Because these 
developments are supported by a small number of retrospective studies, the 
PANDORA study has been introduced: a prospective cohort of all patients 
diagnosed with non-functioning pNET <2cm in the Netherlands. The study 
protocol is presented in Chapter 8. The aim is to investigate the long-term 
effects of non-operative management of small pNET. Tumor progression, 
reasons to refrain from the guidelines and quality of life will be analyzed. 
Patient and tumor characteristics, as well as long-term outcomes of patients 
who receive conservative treatment will be compared against those who 
undergo (initial/delayed) surgery. With this study, we hope to assess the need 
for surgical resection with regards to optimal treatment outcome within 
considerable time. 
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SAMENVATTING 
 
Neuroendocriene tumoren van het pancreas (pNET) zijn zeldzame 
neoplasmata met een groeiende incidentie, met name door het toenemende 
gebruik van geavanceerde radiologische beeldvorming en onze stijgende 
kennis over dit ziektebeeld. Grote, betrouwbare studies met adequate 
patiënten selecties zijn schaars, veelal door de lage incidentie. Hierdoor 
bestaat het beeld bestaat dat de overleving van patiënten met een pNET niet 
lijkt toe te nemen. Om de postoperatieve uitkomsten te verbeteren is het van 
groot belang inzicht te krijgen in de overleving van patiënten met een pNET 
die een chirurgische resectie hebben ondergaan en vervolgens die patiënten 
te identificeren die een grote kans hebben op het krijgen van een recidief. 
Duidelijke en uniforme follow-up adviezen zijn noodzakelijk om recidieven 
vroeg te ontdekken en te behandelen. Dit proefschrift beoogt inzicht te geven 
in de pre- en postoperatieve zorg van patiënten met goed-gedifferentieerde 
pNET (laag tot middelmatig gegradeerde G1 en G2 tumoren) zonder 
afstandsmetastasen of erfelijke syndromen. 
 
Omdat studies met zeldzame ziektebeelden vaak kleine patiënten aantallen 
bevatten, hebben we een grote populatie-studie verricht naar de behandeling 
gerelateerde overleving van patiënten met een pNET. Met behulp van de 
database van de Nederlandse Kanker Registratie (NKR) werden alle 
patiënten, gediagnosticeerd met pNET tussen 2008 en 2013 in Nederland, 
geïdentificeerd. In Hoofdstuk 2 wordt het beloop van deze patiëntgroep 
beschreven. Het blijkt dat gedurende deze periode de algehele overleving 
van de populatie niet toenam. Ongeveer de helft van de patiënten werd 
gediagnosticeerd met afstandsmetastasen. Een hogere Tumor-Klier-
Metastase (TNM) classificatie en tumor gradering bleken significant 
geassocieerd met een slechtere overleving. De meerderheid van de patiënten 
onderging chirurgische resectie, waarbij het aantal geopereerde patiënten 
significant toenam in de tijd. Chirurgische resectie liet betere uitkomsten zien 
in bijna alle subpopulaties. Bij patiënten met de een tumor van de laagste 
classificatie, een pNET <2cm zonder afstandsmetastasen (T1M0), werd er 
een overlevingswinst gezien wanneer zij een resectie hadden ondergaan in 
vergelijking met patiënten die geen behandeling ontvingen. Ook patiënten 
met afstandsmetastasen lieten een betere overleving zien na resectie van de 
primaire tumor. Op dit moment wordt chirurgische resectie alleen 
geadviseerd voor niet-gemetastaseerde pNET >2cm. Onze resultaten stellen 
dat niet alleen bij patiënten met kleine tumoren maar ook patiënten met 
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afstandsmetastasen ten tijde van de diagnose een operatie moet worden 
overwogen, ondanks de huidige richtlijn. 
 
Over het algemeen wordt verondersteld dat recidieven van goed-
gedifferentieerde pNET niet veel voorkomen, gezien het indolente karakter 
van deze tumoren. Omdat er verschillende recidief percentages worden 
beschreven hebben wij in Hoofdstuk 3 een systematische review en meta-
analyse van de bestaande literatuur uitgevoerd om duidelijkheid te scheppen 
over de ware frequentie van recidieven in deze patiëntenpopulatie. Strikte 
inclusiecriteria werden gehanteerd om heterogeniteit te minimaliseren, een 
bekend probleem in pNET onderzoek. Acht studies, bestaande uit 734 
patiënten, voldeden aan de inclusiecriteria. Recidief na curatieve resectie van 
G1 of G2 pNET werd gezien in 9-18%, na een gemiddelde periode van 39,4 
maanden. Subgroep analyse liet zien dat patiënten met G1 tumoren (8%) en 
R0-resecties (microscopisch radicaal) (10%) significant minder vaak een 
recidief ontwikkelden. Afstandsmetastasen, met name in de lever, werden 
vaker gezien dan lokale recidieven of metastasen in regionale lymfeklieren. 
De overleving na een recidief bleek beperkt, met een gemiddelde 
overlevingsduur van 38,9 maanden. Onafhankelijke factoren die werden 
genoemd als voorspellers voor het ontwikkelen van een recidief waren tumor 
grootte, gradering, lymfeklier metastasen, perineurale invasie en irradicale 
resecties. Uit deze studie concluderen wij dat recidieven na curatieve resectie 
van goed-gedifferentieerde pNET niet zeldzaam zijn en derhalve niet moeten 
worden onderschat. 
 
Het identificeren van patiënten met een hoog risico op een recidief kan het 
postoperatieve behandelproces sturen en de ontwikkeling van zowel follow-
up richtlijnen als adjuvante studies ondersteunen. In Hoofdstuk 4 beschrijven 
wij de ontwikkeling van een handig hulpmiddel om het risico op een recidief 
in te schatten voor patiënten die een curatieve resectie hebben ondergaan 
van een niet-functionerende pNET (NF-pNET). In een groot cohort van 211 
patiënten werden recidieven in 17% gezien, na een mediane periode van 43 
maanden. Patiënten die een recidief ontwikkelden, hadden een significant 
slechtere overleving ten opzichte van patiënten zonder recidief. Recidief-vrije 
overlevingscurves lieten zien dat het overgrote deel van de recidieven zich in 
de eerste 5 jaar na operatie openbaarden. Onafhankelijke voorspellers voor 
een recidief waren G2 tumoren, lymfeklier metastasen en perineurale invasie, 
zoals ook in de literatuur wordt beschreven. Met deze voorspellers werd de 
‘Recurrence Score’ ontwikkeld. In dit scoringssysteem krijgen patiënten 
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punten voor de aan- of afwezigheid van deze tumor karakteristieken, waarbij 
de totale score correspondeert met de geschatte kans op het ontwikkelen 
van een recidief binnen 5 jaar na operatie. Interne validatie liet een goed 
onderscheidend vermogen van de Recurrence Score zien, welke hoger was 
dan die van het graderingssysteem van de Wereld Gezondheids Organisatie 
(WHO). Een afkapwaarde van 24 punten bleek het meeste geschikt om hoog- 
en laag-risicopatiënten te onderscheiden, met een sensitiviteit van 91% en 
specificiteit van 62%. Patiënten met een laag risico op recidief (Recurrence 
Score <24) hadden een significant betere overleving dan patiënten met een 
hoog risico op recidief (Recurrence Score >24). In de toekomst kan de 
Recurrence Score gebruikt worden om de postoperatieve follow-up na 
curatieve resectie van een G1 of G2 NF-pNET aan te passen op basis van 
het risico om een recidief te ontwikkelen. Hoog-risicopatiënten zouden baat 
kunnen hebben bij intensieve follow-up of adjuvante therapie om recidieven 
te voorkomen. 
 
Verschillende studies laten zien dat de prognose van pNET sterk afhankelijk 
is van de tumor gradering. Deze wordt bepaald op basis van de Ki67 
proliferatie-index, waarbij G1 tumoren de laagste proliferatie-index hebben 
en G3 de hoogste. Ondanks deze kennis is de postoperatieve follow-up 
hetzelfde voor patiënten met G1 tumoren en patiënten met G2 tumoren, 
onafhankelijk van de Ki67 proliferatie-index, en is adjuvante therapie (nog) 
niet geïndiceerd. Er is veel discussie over de spreiding van Ki67 binnen de 
verschillende graderingen, resulterend in een recente update van het 
graderingssysteem voor hooggradige tumoren. In Hoofdstuk 5 is de 
hypothese dat pNET met Ki67 <20% (niet hooggradige pNET) ook 
heterogeen zijn en een verschillend postoperatief ziektebeloop hebben. In dit 
hoofdstuk hebben wij de rol van de Ki67 index onderzocht in het voorspellen 
van recidieven en de overleving na curatieve resectie van G1/2 pNET. In een 
groot cohort werd gezien dat tumoren met Ki67 6-20% significant vaker een 
recidief ontwikkelde dan tumoren met Ki67 0-5%. Bovendien hadden pNET 
met Ki67 6-20% significant vaker ongunstige tumor karakteristieken. De Ki67 
afkapwaarde van 5% had een redelijk onderscheidend vermogen, met de 
hoogste sensitiviteit en specificiteit voor het voorspellen van een recidief. 
Hoewel het onderscheidende vermogen van dit model vergelijkbaar was met 
die van het bestaande WHO-graderingssysteem, werd een toegevoegde 
waarde gezien met re-classificatie van 10% van de patiënten op basis van 
het risico op het ontwikkelen van een recidief. Naast een Ki67 >5% bleek ook 
tumor grootte >4cm en lymfeklier metastasen onafhankelijke voorspellers 
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voor een recidief. Deze resultaten dragen bij aan het versterken van de 
Recurrence Score, zoals beschreven in Hoofdstuk 4. Door het updaten van 
de criteria voor ‘G2 tumoren’ naar ‘tumoren met Ki67 >5%’ is het mogelijk 
geworden om accurater hoog-risicopatiënten te identificeren. Bovendien 
worden patiënten met Ki67 3-5% (ongeveer 15% in ons cohort) 
gedegradeerd naar laag risico, waardoor overbehandeling kan worden 
beperkt.  
 
De huidige richtlijnen adviseren Chromogranine A (CgA) als de biomarker 
voor het beoordelen van pNET recidieven tijdens de postoperatieve follow-
up. Echter, de klinische toepasbaarheid is twijfelachtig gezien de beperkte 
accuraatheid en frequent vals-positieve resultaten. Recentelijk is de NETest 
geïntroduceerd, een zogeheten ‘liquid biopsy’ (vloeibaar biopsie) techniek, 
die een sensitiviteit en specificiteit van >93% laat zien voor het detecteren 
van neuroendocriene tumoren in het gastrointestinale systeem. In Hoofdstuk 
6 onderzochten wij de prognostische waarde van de NETest, in vergelijking 
met CgA en andere bekende tumor karakteristieken die geassocieerd zijn met 
recidief, om de mogelijke bruikbaarheid in de postoperatieve follow-up van 
patiënten met een pNET te bepalen. In deze prospectieve studie was de 
NETest significant verhoogd in patiënten met een recidief in vergelijking met 
patiënten zonder recidief of irradicale resecties. CgA liet geen verschillen zien 
binnen deze groepen en toonde in verschillende analyses geen positieve 
correlatie met recidief. De NETest bleek een onafhankelijke voorspeller voor 
recidief, samen met tumor gradering, lymfeklier metastasen en tumor grootte. 
Wanneer deze tumor karakteristieken werden gecombineerd met de NETest 
werd er een 91% accuraatheid bereikt voor het voorspellen van een recidief, 
bijna 2 keer hoger dan de tumor karakteristieken alleen. Concluderend is de 
NETest te verkiezen boven CgA als tumormarker en ondersteunt de NETest 
een effectieve identificatie van hoog-risicopatiënten, in het bijzonder wanneer 
het wordt gecombineerd met de Recurrence Score. 
 
Identificatie van hoog-risicopatiënten biedt de mogelijkheid om de 
postoperatieve follow-up aan te passen. Adjuvante behandeling is 
momenteel niet geïndiceerd, maar zou kunnen bijdragen in het voorkomen 
van een recidief na curatieve resectie. Het gebrek aan data over dit 
ziektebeeld, in het bijzonder na curatieve resectie, vormt een grote 
belemmering voor het ontwikkelen van studies die de rol van adjuvante 
behandeling in hoog-risicopatiënten onderzoeken. Hoofdstuk 7 beschrijft de 
resultaten van een consensus studie, een samenwerking tussen 
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verschillende internationale experts in de behandeling van pNET. Het doel 
was om een deel van de belemmeringen weg te nemen en aanbevelingen te 
geven om klinisch onderzoek met adjuvante therapie in patiënten met een 
pNET aan te moedigen. Alle deelnemende experts hebben het risico op het 
ontwikkelen van een recidief na curatieve resectie onderkend en waren het 
erover eens dat er behoefte is aan onderzoek op dit gebied. Een 
gerandomiseerde studie werd geadviseerd, met in beide armen hoog-
risicopatiënten geïdentificeerd met de gemodificeerde versie van de 
Recurrence Score. De brede beschikbaarheid en goede tolerantie heeft 
geleid tot de beslissing om chemotherapie met capecitabine en 
temozolomide (CapTem) te adviseren als adjuvante behandeling. Echter, de 
studiegroep benadrukt dat ook Peptide Receptor Radionuclide Therapie 
(PRRT) veelbelovende resultaten laat zien en adviseert deze te heroverwegen 
wanneer de beschikbaarheid van deze behandeling is toegenomen. Power 
berekeningen op basis van gepubliceerde resultaten van CapTem in 
patiënten met een vergevorderde ziekte laten zien dat een multicenter 
benadering noodzakelijk is om adequate patiënten aantallen te verzamelen 
en betrouwbare resultaten te bereiken.  
 
Lange tijd was chirurgische resectie de gouden standaard voor pNET zonder 
afstandsmetastasen. Recentelijke studies beschrijven echter nauwelijks tot 
geen progressie met een excellente prognose en lage morbiditeit voor kleine 
pNET, wanneer van opereren wordt afgezien. Op basis van dergelijke 
resultaten heeft de European Neuroendocrine Tumor Society (ENETS) 
recentelijk zijn richtlijnen aangepast, waarbij een afwachtend beleid voor 
kleine niet-functionerende tumoren wordt geadviseerd. Omdat dit advies op 
een kleine aantal retrospectieve studies is gebaseerd, is de PANDORA-studie 
opgezet: een prospectief cohort van alle patiënten met een niet-
functionerende pNET <2cm in Nederland. Het studieprotocol wordt 
gepresenteerd in Hoofdstuk 8. Het doel is om de lange-termijn effecten van 
deze niet-operatieve behandeling van kleine pNET te onderzoeken. Tumor 
progressie, redenen om af te zien van de huidige richtlijnen en kwaliteit van 
leven zullen worden geanalyseerd. Patiënt- en tumor karakteristieken van 
patiënten die een conservatieve behandeling ondergaan zullen worden 
vergeleken met patiënten die een primaire resectie ondergaan. Met deze 
studie hopen wij binnen afzienbare tijd de noodzaak voor chirurgische 
resectie in relatie tot een optimaal behandelresultaat te kunnen bepalen. 
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1. PhD training 
Year  Workload (ECTS) 
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Systematic Review Writing      2017  0.7 
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Weekly Department Seminars    2015-2017 3.5 
Journal Club      2015-2017 3.0 
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Management and survival of pancreatic neuroendocrine tumors  
in the Netherlands. 
   World Congress of Surgery, Basel, Switserland.  2017  0.5 
   European-African HPB Association, Mainz, Germany.  2017  0.5 
 
Nomogram to predict recurrent disease in grade 1 and  
2 non-functional pancreatic neuroendocrine tumors. 
   Chirurgendagen, Veldhoven, the Netherlands.   2016  0.5 
   European Society for Surgical Research, Prague, Czech Rp. 2016  0.5 
 
Poster presentations 
The clinical value of circulating transcript analysis (NETest) during  
follow-up of resected well-differentiated pancreatic neuroendocrine  
tumors. 
   Annual Conference of the European Neuroendocrine Tumors  2018  0.5 
   Society, Barcelona, Spain.  
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Management and survival of pancreatic neuroendocrine tumors  
in the Netherlands. 
   European Pancreatic Club, Liverpool, England.   2017  0.5 
   European Neuroendocrine Tumor Society, Barcelona, Spain. 2017  0.5 
   European-African HPB Association, Mainz, Germany.  2017  0.5 
   World Congress of Surgery, Basel, Switserland   2017  0.5 
 
Ki67 to Predict Recurrence and Survival of Pancreatic  
Neuroendocrine Tumors. 
   Annual Conference oft he European Neuroendocrine   2017  0.5 
   Tumors Society, Barcelona, Spain 
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neuroendocrine tumors. 
   Annual Conference of the European Neuroendocrine Tumors  2017  0.5 
   Society, Barcelona, Spain. 
   European-African HPB Association, Mainz, Germany.  2017  0.5 
   American Association of Endocrine Surgeons, Orlando, USA. 2017  0.5 
   European Pancreatic Club, Budapest, Hungary.   2017  0.5 
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pancreatic neuroendocrine tumors. 
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Year  Workload (ECTS) 
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University of Amsterdam.     
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E. Ronde, bachelor student AMC    2017  1.0 
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Other 
NETwerkgroep AMC     2015-2017 1.0 
Reviewer for the Amsterdam Medical Students Journal  2016-2017 1.0 
Research Fellowship WREN Laboratory, USA   2017  4.0 
Organization NET Patient Day AMC    2016  0.5 
 
 
 
1. Parameters of Esteem 
Year   
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Lisa Waller Hayes Foundation Research Grant    2017 
IPSEN Science Travel Award      2017   
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DANKWOORD 
 
Promoveren doe je nooit alleen. Zonder de hulp van een aantal bijzondere 
mensen was het mij nooit gelukt dit proefschrift te verwezenlijken, laat staan 
af te maken. Voor hen een bijzonder bedankje. 
Allereerst mijn promotor, professor dr. C.H.J. van Eijck. Beste Casper, 
bedankt dat je in mijn enthousiasme en doorzettingsvermogen hebt geloofd 
dat ene moment tijdens mijn artsexamen. Je eerlijkheid heb ik altijd enorm 
gewaardeerd en gaf me een extra stimulans om het beste uit mezelf te halen. 
Je hebt mij de kans geboden om mij verder te ontwikkelen en te kunnen 
bereiken waar ik nu ben. Dit is van onschatbare waarde.  
Dr. E.J.M. Nieveen van Dijkum, beste Els, als co-promotor en dagelijks 
begeleider was dit proefschrift er nooit geweest zonder jou. Je hebt mij veel 
vertrouwen en vrijheid gegeven om de onderzoeken vorm te geven, maar ook 
om deze te combineren met het leven buiten het AMC. Ondanks de velen 
buitenlandtripjes heb je nooit in mij getwijfeld. Ik had je aan het begin belooft 
dit project in een korte periode tot een succes te brengen, en het is gelukt! 
Bedankt voor je steun hierbij. 
Graag wil ik de leescommissie, Prof. Dr. W.W. de Herder, prof. dr. L.J. 
Hofland en dr. H.J. Klümpen bedanken voor het kritisch lezen van het 
manuscript. In het bijzonder dr. Heinz-Josef Klümpen; je hebt mij als 
copromotor begeleid, geadviseerd en geholpen bij een aantal van de 
onderzoeken in dit proefschrift. Bedankt voor je altijd kritische blik en 
laagdrempelige overleg.   
De overige leden van de promotiecommissie wil ik bedanken voor hun 
bereidheid als opponent deel te nemen in de grote commissie: prof. dr. R. de 
Krijger, dr. R.A. Feelders, dr. J. Hofland. 
Dear colleagues from Italy, especially prof. Massimo Falconi. My PhD started 
with a collaboration between our centers and from there leaded to many more 
collaborations and some very nice publications. Many thanks for joining 
forces in improving the treatment of this rare disease.  
Dear prof. Irvin Modlin, dr. Mark Kidd and all other colleagues from the Wren 
Laboratories: thank you for giving me the opportunity to work with you on the 
NETest. I have learned so much from you during our time together in 
Branford. Your intensive guidance has helped me to bring this project to a 
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success, while you gave me the freedom to make this project my own. A rare 
combination that has been so valuable.  
Lieve paranimfen, zonder jullie was mijn periode op G4 een stuk kleurlozer 
geweest. Bedankt dat jullie er altijd voor mij waren en deze tijd onvergetelijk 
hebben gemaakt. Lieve Lianne, we zijn samen begonnen en voor mijn gevoel 
hebben we samen alles meegemaakt. Van begin tot eind was er een klik en 
ik ben heel blij dat we beide bij de HPB zaten zodat we ook een aantal 
congressen samen hebben kunnen meepakken. Hopelijk heel snel ook 
samen in de OK! Lieve Kwee, vanaf het eerste assistent-onderzoekers 
weekend was het aan en daar ben ik heel blij mee. Ondanks dat we beiden 
in het ziekenhuis totaal andere dagtaken hadden, lopen we op persoonlijk 
vlak verbazingwekkend synchroon. Gedeelde smart is halve smart maar 
gedeeld geluk is dubbel geluk. Ik ben heel blij dat jij mijn paranimf wil zijn! 
Alle overige chirurgen van het AMC wil ik bedanken voor de prettige 
samenwerking en de leerzame momenten. In het bijzonder wil ik prof. Marc 
Besselink bedanken voor de zijdelingse overlegmomenten en adviezen en de 
efficiënte introductie van de PANDORA-studie binnen de DPCG. 
Aan de (enorme) groep onderzoekers en arts-assistenten van G4: dank voor 
jullie hulp, adviezen, lunches, gezelligheid, borrels, feestjes, klaagmomenten, 
colaatjes en congressen. Ik zal de mooie arts-assistent/onderzoekers-
weekenden en natuurlijk de wintersporten niet vergeten. 
Lieve clubgenoten en vriendinnetjes van ‘t gym, ondanks dat ik me afvraag 
of jullie ooit echt hebben begrepen waar ik mee bezig was, hebben jullie altijd 
voor mij klaar gestaan. Bij elk baalmoment boden jullie mij een luisterend oor 
en verfrissende adviezen (soms heb je een blik van buitenaf nodig); elk 
succes vierden jullie met mij mee. Lieve Laura en Ellen, jullie eeuwige geduld 
voor het luisteren naar mijn klaagzang is bewonderenswaardig, jullie zijn de 
beste! Mede dankzij jullie support is dit proefschrift tot een goed einde 
gekomen.  
Aan alle collega’s van het Spaarne Gasthuis: door jullie voel ik mij vanaf het 
begin welkom in de kliniek. Bedankt voor jullie gezelligheid en steun, in het 
bijzonder rondom ontwikkelingen in mijn chirurgische carrière. Door jullie 
aanmoediging zal ik binnenkort starten aan de opleiding binnen Regio 1. 
Supermegabedankt! 
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Mijn familie heeft altijd onvoorwaardelijk achter mij gestaan en elke stap van 
dit proefschrift tot op de voet gevolg. Allerliefste mama, jij bent mijn grootste 
fan en ik kan altijd op jouw steun en adviezen vertrouwen. Met je 
superscherpe intuïtie heb je mij door verschillende momenten heen geholpen. 
Bedankt dat ik altijd op je kan terugvallen. Lieve papa, bedankt dat je altijd 
trots op mij bent, maakt niet uit wat ik doe. Tegenslagen lijken door jouw 
positieve instelling net iets minder erg. En natuurlijk mijn allerliefste zus, jij 
bent mijn favoriet! Ups en downs maken we samen mee en beiden worden 
we steeds volwassener. Heel snel gaan we ook jouw successen vieren en wie 
weet wordt je ooit nog slimmer dan ik. Maar voor nu: shotgun promoveren! 
Liefste Anton, zonder jou was dit proefschrift er niet geweest en zonder dit 
proefschrift was jij er niet geweest. Ik ben dankbaar dat jij in mijn leven bent 
gekomen. Jij maakt alles makkelijker, zelf het schijven van een proefschrift. 
Bedankt voor alles. Ik heb je lief.  
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